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Abstract 
Colorectal cancer (CRC) is one of the most common types of cancer both worldwide and in 
Norway. Risk factors and mechanisms contributing to the disease are among dietary and 
lifestyle and somatic and inherited mutations. CRC is divided in three groups 1. Sporadic 
CRC where the patients have no family history and no identifiable mutations; 2. Familial 
CRC where the majority of genetics are unknown but the patients have at least one blood 
relative, but no specific germline mutation or clear inheritance pattern; 3. Hereditary CRC 
syndromes where the patients have inherited a single gene mutation in highly penetrant cancer 
susceptibility genes. The genes known to date to predispose to colorectal cancer are APC, 
BMPR1A, POLE, SMAD4, the MMR genes among others and these genes are related to the 
hereditary CRC syndromes. There are other genes which have been found in Genome-wide 
association studies (GWAS), exome studies or with next-generation sequencing (NGS) to be 
associated with CRC such as KLLN, AKT1, PIK3CA, OGG1, KIF23 among others. 123 
genes some known to be involved in hereditary CRC syndromes and some associated with 
CRC were sequenced in 95 patients using Haloplex targeted NGS. The purpose for this master 
thesis was to identify pathogenic variants in these genes that could be of help to explain the 
increased CRC risk in these patients.  
The results from the NGS identified 1268 unique variants which were filtered with the 
downstream analysis tool FILTUS. After the variants found in only one or two patients were 
selected. 64 unique variants were left to be further evaluated using the prediction software 
Alamut. From the 64 variants 25 variants were selected to further investigate because those 
were found to have most prominent effects on the proteins. Four out of the 25 variants were 
found to be involved in predisposition to hereditary CRC syndromes; two variants identified 
in POLE, a variant in BMPR1A and a variant in PTEN. The other variants identified may be 
involved in CRC predisposition, but further functional studies are needed to determine their 
function in CRC involvement. There were identified a few false positive variants during the 
use of Haloplex targeted NGS, but because the rate of these variants were not high this 
method seems to be a reliable method to use in cancer research.  
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1. Introduction 
1.1 Colorectal cancer 
Colorectal cancer (CRC) is a disease that affects the epithelium of the colon and the rectum, 
and is one of the most common types of cancer both worldwide and in Norway [1, 2]. With 
more than a million new cases every year, CRC is responsible for about 15% of all the 
cancers [1, 2]. Risk factors and mechanisms contributing to this disease are among dietary and 
lifestyle factors and somatic and inherited mutations [3]. There are three major pathways 
associated with CRC that account for the majority of the CRC cases: Chromosomal instability 
(CIN), microsatellite instability (MSI), and CpG island methylation phenotype [4].  
CRC is divided into three groups: 1. Sporadic CRC which accounts for about 60% of the 
cases and include patients with no family history and no identifiable inherited gene mutation; 
2. Familial CRC (FCC), accounting for about 20-30% of the cases and where the patients 
have at least one blood relative with CRC or an adenoma, but has no specific germline 
mutation or clear inheritance pattern [5, 6]; 3. Hereditary CRC syndromes account for 
approximately 5-10% of the cases where the patients have inherited only a single gene 
mutation in highly penetrant cancer susceptibility genes. [2, 6] Family history is therefore a 
big risk factor with a lifetime risk of 10-15% if a first degree relative has CRC, and 30-100% 
in familial genetic syndromes [7]. 
The outcome for patients with CRC is dependent on which stage the disease has reached at 
diagnosis, but the odds for survival normally varies from a 90% 5-year survival rate if the 
cancers are detected at the localized stage to 10% for individuals that are diagnosed with a 
distant metastatic cancer [8]. Therefore it is important for at-risk individuals with early 
detection of CRC due to improved prognosis and a precise understanding of the genetics 
behind inherited CRC. Early detection of CRC also improves cancer surveillance and 
prevention strategies, and helps to develop better diagnostic and therapeutic approaches. [5]  
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1.1.1 Molecular genetics in CRC 
The factors behind CRC development are many and they appear to be both complex and 
heterogenous. Both dietary and lifestyle factors and inherited and somatic mutations 
contribute to CRC, and the most significant dietary and lifestyle factors seem to be a diet rich 
with unsaturated fats and red meat, total energy intake, excessive alcohol consumption and 
reduced physical activity. However, factors that are likely to protect against CRC are 
nonsteroidal anti-inflammatory drugs, estrogen, calcium and possibly some statins. [3] The 
process leading to CRC is like any other cancer due to a series of multigene events, and a 
study by Vogelstein et al. [9] suggested that the progression towards CRC could be due to a 
series of four genetic events: alteration of APC, K-ras, DCC and p53. The alterations of these 
genes follow a certain order meaning that the former gene alteration leads to the latter event. 
[9] A figure of these events can be seen under in figure 1.1.   
 
Figure 1.1. Overview of the gene mutations in chronological order that is suggested to lead to CRC, 
where the mutation in the APC gene initiates the series of mutational events [10].  
According to Knudson’s two-hit hypothesis mutations in tumor suppressor genes (TSGs) that 
are inherited will not alone cause tumorigenesis. This is because there is still one healthy copy 
of the gene in every cell in the body. A cell will not lose its function until the second copy of 
the gene has turned nonfunctional and Knudson’s two-hit hypothesis suggests that this is due 
to a somatic mutation. [11, 12] 
The hereditary CRC cases are as mentioned previously divided in two groups: hereditary CRC 
syndromes where the genetic cause is known and FCC where the genetics behind the majority 
of cases are unknown. The most likely cause of FCC is a combination of alterations in high 
penetrant single genes and low penetrant- and multigenes. Common polymorphisms in genes 
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regulating metabolism or genes regulated by environmental or other genetic factors are 
examples of this. [5]  
Genes known to date to predispose to CRC are APC, BMPR1A, CDH1, POLE, MUTYH, 
SMAD4, STK11 and the MMR genes among others. These genes are high penetrant and are 
related to the hereditary CRC syndromes. Other genes such as KLLN, AKT1, PIK3CA, 
OGG1, KIF23 among others have been found to be associated with CRC in genome wide 
association studies (GWAS), exome studies or with next-generation sequencing. In GWAS 
single nucleotide polymorphisms (SNPs) that have moderate or low penetrance are studied to 
determine their function in disease. The full names of the known genes can be found under a 
list of abbreviations (see page V).  
 
1.2 Syndromes known to cause hereditary CRC 
1.2.1 Lynch Syndrome  
Lynch syndrome, also known as Hereditary Nonpolyposis Colorectal Cancer (HNPCC) is 
responsible for about 2-4% of the hereditary CRC cases, making it the most common cause of 
hereditary CRC [2]. Lynch syndrome was earlier diagnosed in families that fulfilled the 
Amsterdam criteria (AC) I which was later modified to AC II so that the extra-colonic cancers 
could be included. An overview of these criteria can be seen in table 1.1. In the present day it 
has become clear that not all AC positive families have Lynch syndrome. This was because 
the cause of MSI was identified which is loss of mismatch repair activity, and this led to the 
discovery of the genes that cause Lynch syndrome. [4] 
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Table 1.1. Overview of the Amsterdam Criteria [4].  
Amsterdam Criteria I Amsterdam Criteria II 
At least three relatives with CRC and the following:  At least three relatives with HNPCC-related 
cancers (colorectal, endometrial, small bowel, 
ureter or renal pelvis) and the following: 
One should be a first degree relative of the other two One should be a first degree relative of the other 
two 
At least two consecutive genereations should be 
affected 
At least two consecutive generations should be 
affected 
At least one case of colorectal cancer should be 
before age 50 
At least one case of HNPCC-related cancer should 
be before age 50 
Familial adenomatous polyposis should be excluded 
in any cases of CRC 
Familial adenomatous polyposis should be 
excluded in any cases of CRC 
Verfication of tumors’ histopathology  Verification of tumors’ histopathology 
The syndrome is caused by a germline mutation in one of the MMR genes: MLH1 (MIM 
#120436), MSH2 (MIM #609309), MSH6 (MIM #600678) and PMS2 (MIM #600259), and 
has an autosomal dominant inheritance pattern [2]. This syndrome is not described in detail 
because the MMR genes were not the focus of this study, it was the focus of another master 
thesis.  
 
1.2.2 Familial Adenomatous Polyposis 
FAP is an autosomal dominant syndrome, and it is one of the common inherited CRC 
syndromes having a prevalence of 1 in 10 000 individuals. The typical traits for classic FAP 
are development of several up to thousands of colonic adenomas which starts early in 
adolescence, and will continue to CRC if untreated [2, 5]. Individuals with the classic form of 
FAP have an average lifespan of about 39 years with untreated CRC, and approximately 95% 
will have developed CRC at the age of 50. A less severe form of the syndrome is attenuated 
FAP where there are fewer colonic adenomatous polyps with an average of 30 polyps and the 
maximum being about a 100. The average age of onset is higher, also individuals with this 
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form of the syndrome will develop polyps and CRC at a later age and the average lifetime risk 
of CRC is 69%. [5] There are several extra-colonic cancers that take place in FAP such as 
duodenal cancer, which is the second most common of the extra-colonic cancers in FAP, 
fundic gland polyps are also common although they do not have a high cancer risk. Gastric 
adenomas on the other hand have a higher risk towards the development of cancer but they 
are not all that common.[2] The cause of both classic and attenuated FAP is the germline 
mutations in the adenomatous polyposis coli (APC; MIM #611731) gene which is a tumor 
suppressor acting as an antagonist in the WNT signaling pathway [2, 13]. The gene is also 
involved in processes such as cell migration and adhesion, transcriptional activation and 
apoptosis. The mutations which are associated with disease have a tendency to cluster in a 
small region called the mutation cluster region (MCR) and this results in a truncated protein. 
[13] There have been identified more than 1000 APC variants that cause truncated protein 
products due to premature stop codons or frameshifts [2]. 
Classic FAP is diagnosed if at least 100 polyps are identified, whereas attenuated FAP 10 or 
more but fewer than 100 polyps have to be present. To diagnose attenuated FAP can 
sometimes be difficult, since the number of polyps can vary with this syndrome and also 
because it can mimic classic FAP and other syndromes such as MUTYH-associated polyposis 
(MAP), Lynch syndrome and even sporadic polyp development.[5, 14] 
 
1.2.3 MUTYH-Associated Polyposis 
MUTYH-Associated Polyposis (MAP) is an autosomal recessive inherited syndrome where 
the typical traits are adenomatous polyposis present in the colorectum and an increased risk of 
CRC [5, 15]. The genetic cause of this syndrome is due to biallelic mutations in the gene 
MutY homolog (MUTYH; MIM #604933) [5, 16]. MUTYH has the cytogenetic location 
1p34.1 and encodes a DNA glycosylase which is part of the base-excision pathway by 
participating in the oxidative DNA damage repair process [2, 16]. The actual function of 
MUTYH is to help make sure that G:C to T:A transverions into highly mutagenic bases due to 
oxidative stress do not occur [5]. 
The patients usually develop colonic polyposis by the age of 40 even though development of 
polyps and cancer can take place earlier [5]. Adenomatous polyps dominate in MAP where 
the patients usually develop an average of about 50 polyps, but there have also been cases 
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with serrated polyps and unlike attenuated FAP hyperplastic polyps are common [2, 5, 15]. 
There have also been reported cases of MAP that did not show a polyposis phenotype. 
Extracolonic cancers can also occur in this syndrome where those described are breast-, 
gastric-, thyroid-, testis- and hematologic cancer. [15] 
Criteria for diagnosing MAP have not quite been fully established, but for now the MAP 
phenotype is considered similar to attenuated FAP. Diagnosing MAP according to genetics 
will confirm the syndrome and will allow for genetic testing of family members. [5]   
 
1.2.4 Polymerase Proofreading –Associated Polyposis 
According to the study by Palles et al. [17] a new hereditary CRC syndrome Polymerase 
Proofreading-Associated Polyposis (PPAP) has been identified where the cause is germline 
mutations in Polymerase DNA directed epsilon, catalytic subunit (POLE; MIM #174762) and 
Polymerase DNA directed delta 1, catalytic subunit (POLD1; MIM #174761) [8, 18, 19]. 
POLE encodes the catalytic subunit of DNA polymerase epsilon, where the enzyme is 
involved in DNA repair and chromosomal DNA replication [17, 18]. During the DNA 
replication POLE is responsible for the synthesis of the leading strand. POLE also has proof-
reading capacity through the POLE exonuclease domain which is important for maintenance 
of replication fidelity. This capacity does not only act on newly misincorporated bases but 
may also act on mismatches that are produced by non-proof reading polymerases like Polα. 
[17] POLD1 is also involved in DNA replication and repair where it participates in the 
mismatch and base excision repair pathways [17, 19]. The gene encodes the catalytic and 
proof-reading subunit of DNA polymerase delta, which is the equivalent lagging strand 
polymerase to POLE [17]. 
PPAP is a dominant inherited syndrome which predisposes to the development of several 
colorectal adenomas and carcinomas. POLE and POLD1 are both involved in proofreading 
activity and in patients with this syndrome this proofreading exonuclease activity is impaired 
due to mutations in these genes. [20]  
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1.2.5 Hamartomatous Polyposis Syndromes  
Hamartomatous Polyposis syndromes (HPS) are a group of rare hereditary genetic autosomal 
dominant disorders that cover less than 1% of all the hereditary CRCs. HPS includes Peutz-
Jeghers syndrome (PJS), Juvenile polyposis syndrome (JPS), PTEN hamartoma tumour 
syndrome (PHTS) which includes Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba 
syndrome (BRRS), and characteristic traits for all these syndromes are the Hamartomatous 
polyps. These polyps are in themselves benign comprised of cells that are indigenous in the 
area that they are found in, but these syndromes have a malignant potential to develop both 
CRC as well as extracolonic cancers.[21]  
 
1.2.5.1 Peutz-Jeghers syndrome 
In PJS the hamartomatous polyps occur in the gastrointestinal tract [22]. Characteristics for 
the PJS polyps are that they are usually multilobulated with a papillary surface with branching 
bands of smooth muscle covered by hyperplastic glandular mucosa [23]. The consequence of 
gastrointestinal polyps can be gastrointestinal bleeding, anemia and abdominal pain caused by 
intussuception, obstruction or infarction [22]. Another characteristic trait with this syndrome 
is that it causes mucocutanous hyperpigmentation of the lips, buccal mucosa and digits [24].  
PJS also has a high rate of extracolonic cancers such as gastric, small bowel, pancreatic, 
breast, ovarian, lung, cervical and uterine/testicular cancer [2].  
To diagnose this syndrome there has been a few criteria proposed: (1) There have to be 
findings of three or more Peutz-Jeghers (PJ) polyps confirmed histologically; (2) Family 
history with PJS; (3) Mucocutanous pigmentation that is characteristic and prominent with a 
family history of PJS; (4) Both mucocutanous characteristic and prominent pigmentation and 
any number of PJ polyps [25].   
PJS can occur due to germline mutations in the serine threonine kinase 11 gene (STK11; MIM 
#602216) [22]. These germline mutations have been documented in about 70-80% of the 
patients with PJS where about 15% of the cases part or all of STK11 had been deleted [24].  
The function of this gene is complex and is still being researched, but it seems to be a tumor 
suppressor gene and has been found to regulate the cell cycle, mediate apoptosis, and cellular 
polarity including other functions [2, 22, 25].  
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1.2.5.2 Juvenile Polyposis Syndrome 
JPS is characterized by juvenile polyps that usually occur throughout the gastrointestinal tract 
[2]. These polyps appear as spherical and microscopically they are characterized by 
overgrowth of an oedematous lamina proparia (mucus membranes or mucosa), with 
inflammatory cells and cystic glands [23]. This syndrome carries an increased risk of CRC 
and diagnostic criteria according to the World Health Organization (WHO) require one of the 
following: (1) having more than five polyps in the colon or rectum; (2) having Juvenile polyps 
present in the gastrointestinal tract; (3) Patients with juvenile polyps having a family history 
of JPS. [2]  
JPS can occur due to a germline mutation in one of the three genes SMAD4 (MIM #600993), 
BMPR1A (MIM #601299) and ENG (MIM #131195), all related to transforming growth 
factor-beta (TGF-beta). Mutations in SMAD4 and BMPR1A are each found in approximately 
20% of patients with JPS.[2] The BMPR1A gene is located in the same chromosomal region 
as the PTEN gene, and there have been reported large deletions in both genes. These patients 
show a more severe form of the syndrome with onset in early childhood or symptoms of both 
CS and JPS. [23]  
 
1.2.5.3 Cowden Syndrome 
PHTS includes patients that clinically have CS and BRRS. The germline mutation of the 
phosphotase and tensin homolog PTEN (MIM # 601728) gene can be the cause of both these 
syndromes. Both CS and BRRS are rare syndromes where BRRS is mostly present in the 
pediatric population whereas CS is most commonly present in adults. [2]  
CS is a disease with variable penetrance where traits such as multiple hamartomatous and 
neoplastic lesions of the skin, mucous, membranes, thyroid, breast, colon, endometrium and 
brain can be seen [26]. The mutations that occur in the PTEN gene which are associated with 
CS, are usually point mutations, smaller deletions or insertions [23]. PTEN is a tumor 
suppressor gene and in approximately 85% of probands with CS there have been identified 
germline mutations in this gene [26, 27]. PTEN encodes the protein phosphatidylinositol-3, 4, 
5-triphosphate 3-phosphatase containing the two domains, a tensin like domain and a catalytic 
domain which is similar to the dual specificity protein tyrosine phosphatases. This protein 
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unlike the other protein tyrosine phosphatases, dephosphorylates phosphoinositide substrates 
and also negatively regulates the intracellular levels of phosphatidylinositol-3,4,5-
triphosphate in cells.[28] The protein accomplishes this by antagonizing the 
phosphatidylinositol-triphosphate kinase (PI3K) signaling pathway through its lipid 
phosphatase activity which results in the following inhibition of the Akt proto-oncogene [27]. 
It also functions as a tumor suppressor because it negatively regulates the AKT/PKB signaling 
pathway [28]. The phosphatase activity of the encoding protein regulates the mitogen-
activated protein kinase (MAPK) pathway in a negative manner according to Gu et al. [29]. 
Inactivation or loss of function of PTEN will in the mentioned signaling pathways, cause 
increased cell survival and uncontrolled cellular proliferation, followed by neoplasia as seen 
in many human cancers [27].  
 
1.2.6 Syndromes associated with hereditary CRC 
1.2.6.1 Hereditary diffuse gastric cancer 
Hereditary diffuse gastric cancer (HDGC) is a cancer syndrome with an autosomal dominant 
inheritance pattern and is caused by germline mutations in the genes Cadherin 1, type 1, E-
cadherin (CDH1; MIM #192090) and Catenin (Cadherin associated protein) alpha 1, 102 kDa 
(CTNNA1; MIM #116805). CRC has been observed in this syndrome in patients belonging to 
families positive for CDH1. 
 
1.2.6.2 Oligodontia-Colorectal cancer syndrome 
Oligodontia is the genetic explanation for severe tooth agenesis, where the characteristics are 
congenital lack of six or more permanent teeth. It is a very rare disease and is usually related 
with some multiorgan syndrome. In the study by Lammi et al. [30] it was found that 
Oligodontia may have a connection to susceptibility for hereditary CRC. The cause of 
Oligodontia and predisposition to cancer was found to be a nonsense mutation Arg656Stop in 
the Axis inhibitor 2 (AXIN2; MIM #604025) gene. [30] Mutations in this gene are associated 
with CRC with defective mismatch repair. [31]  
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1.3 Other associations with CRC  
There have been several studies that have found genes to be associated with CRC and some of 
these studies are described here. In a study by Alhopuro et al. [32] MYH11 (MIM #160745) 
was examined whether not it had a mononucleotide tract in its coding sequence since these 
tracts are vulnerable to mutations under MSI. The study by Bennett et al. [33] identified a 
hypermethylation in PTEN that resulted in downregulation of KLLN (MIM #612105) through 
transcription. In another study executed by Gylfe et al. [34]  there were identified 14 
truncating germline variants in eleven novel predisposing genes in at least two families with 
CRC. The genes identified were: AKR1C4 (MIM #600451), CCDC18, MRPL3 (MIM # 
607118), NUDT7 (MIM #609231), PRADC1, PRSS37, PSPH (MIM #172480), SFXN4 
(MIM #615564), TWSG1 (MIM #605049), UACA (MIM #612516) and ZNF490 [34]. 
DeRycke et al. [7] found CENPE (MIM #117143) and KIF23 (MIM #605064) to include 
novel missense variants in the susceptibility for FCC. The studies by Smith et al. [35] and 
Kim et al. [36] identified variants in the OGG1 (MIM #601982) gene that were associated 
with CRC. In a study by Kokko et al. [37] four heterozygous missense variants that were 
previously unreported were identified in EPHB2 (MIM #600997). Two studies by Guda et al. 
[38] identified two somatic and seven germline mutations in the GALNT12 (MIM #608812) 
gene that were associated with CRC.  
The MYH11 gene produces two splice variants SM1 and SM2, which are distinct in the C-
terminal tailpiece. In the study by Alhopuro et al. [32] a mononucleotide repeat of 8 cytosines 
(C8) was observed in the SM2 isoform, and MYH11 was therefore discovered as a candidate 
MSI colon cancer gene. Mutations that were found during this study were protein-elongating 
frameshift mutations found in 55% of the CRC cases that exhibited MSI meaning somatic 
mutations, and also found in the germline of an individual with PJS. There were also 
discovered two somatic missense mutations in one microsatellite stable (MSS) CRC. All the 
mutations led to unregulated molecules that showed constitutive motor activity. [32]  
In the study by Bennett et al. [33] the hypermethylation upstream of PTEN were detected in 
45 out of 123 patients with CS or Cowden-Like syndrome (CSL). The result of the germline 
methylation was including downregulation of KLLN also disruption of TP53 activation of 
KLLN by approximately 30%. The study found that the epigenetic modification accounted for 
one-third of CS individuals negative for germline PTEN mutation and more than 40% of 
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those with CS who were PTEN mutation negative had germline epigenetic inactivation of the 
KLLN promoter. [33]   
The results from the study by Gylfe et al. [34] showed that out of the eleven genes identified 
four showed loss of the wild-type allele in at least one tumor and a total of seven events with 
loss of heterozygosity (LOH) were detected, although none showed loss of the mutant allele. 
This proposes that complete inactivation of these genes is suitable for tumor development and 
also that these variants are major candidates for CRC susceptibility. Two of the genes that 
were of particular interest were UACA and TWSG1. This was due to that three out of 96 
familial CRC cases were found to have heterozygous truncating variants in UACA and in 
TWSG1. [34] 
The study by DeRycke et al. [7] found that the missense variants identified in KIF23 and 
CENPE were rare. The variant found in KIF23 was only observed in the ESP database of 
European Americans, but the CENPE variant was not seen in any of the public databases. 
Both of these variants were validated and replicated and both are located in previously 
reported CRC linkage regions. [7] 
In the study by Smith et al. [35] the variant identified in OGG1 was a rare inherited 
nonsynonymous variant with an over representation in patients suffering from advanced CRC 
compared to population based control subjects [35]. The variant identified was a Gly308Glu 
substitution and because Glycine at residue 308 through evolution had been much conserved 
it was predicted that the Glutamic acid substitution would interfere with function. The results 
of the study showed infrequently biallelic inherited and somatic OGG1 mutations in carriers 
of OGG1 Gly308Glu and no associated somatic mutator phenotype was observed. This 
suggests that the variant may play a role as a low-penetrance allele contributing to colorectal 
tumorigenesis. [35] In the study by Kim et al. [36] the variant discovered was a R154H 
polymorphism and it was present in patients with FAP, sporadic CRC and in normal controls. 
R154H was found to be associated with sporadic CRC patients, but did not segregate with 
cancer phenotypes. The results from the study also showed that there was low possibility of 
recessive inheritance of R154H, but this still needs to be elucidated. [36] 
The study by Kokko et al. [37] found that two of the variants I361V and R568W in EPHB2 
were identified in Finnish CRC patients, and the third variant D861N was identified in a UK 
patient with hyperplastic polyposis (HPP). The fourth variant R80H was identified in a 
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Finnish patient with CRC and was also found in 1 of 206 familial CRC patients and in 9 of 
281 healthy controls and therefore it is likely that this variant might be a neutral 
polymorphism. The results altogether suggest that EPHB2 may play a limited role in CRC 
predisposition and that it plays a bigger role in tumor progression rather than in tumor 
initiation. [37] 
The results from the study of 30 MSS colon cancer cell lines by Guda et al. [38] showed that 
the two somatic mutations identified in GALNT12 were both found in the primary colon 
tumors from which the cell lines were established, and absent in the normal colon tissues from 
the same patients. It was also found that these two mutations were within the GALNT12 
catalytic and lectin binding domains. The study proved that the two somatic mutations 
completely inactivated the enzymatic activity of GALNT12, but the wild type GALNT12 
allele was found to be retained and expressed in both tumors with the inactivating mutations. 
[38] In the other study by Guda et al. [38] which was performed to see whether germline 
mutations in GALNT12 contributed to the development of colon cancer, six of the seven 
germline variants identified encoded inactive GALNT12 enzymes. [38]   
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1.4 Next-Generation Sequencing  
Next-generation sequencing (NGS) is a term that refers to a rapid evolving high-throughput 
technology field,  that is capable of producing large numbers of DNA sequences in parallel 
very efficiently, making it a less costly and time consuming method than the earlier 
technologies used to sequence parts of the human genome, such as Sanger sequencing and 
fluorescence-based technologies [39-41]. NGS is a useful tool in cancer studies due its ability 
to not only sequence whole genomes but also focus on specific genomic regions or specific 
genes using DNA capturing methods. [40]. The NGS workflow is built up of four phases: 
sample collection, template generation, sequence reactions and detection and data analysis. 
The template has to be converted into a library of sequencing reaction templates that includes 
the common steps fragmentation and step size selection, which serve to break the DNA 
templates into smaller fragments suitable for sequencing. The template generation enables 
separation and immobilization of the DNA fragment population, thus making it possible for 
the downstream sequencing reactions to operate while millions of micro reactions are carried 
out in parallel on each template. To discover structural variants such as insertions, deletions 
and translocations sequence coverage of approximately 20x to 30x is required to overcome 
the uneven read distributions and sequencing errors. Biases can be introduced during all steps 
of NGS and the best example of this is during the template amplification steps. In these steps 
mutations can be introduced into clonally amplified DNA templates which subsequently 
masquerade as sequence variants. [41]  
 
1.4.1 Targeted Sequencing 
Targeted sequencing is a technique that is very useful in cancer research due its ability to 
focus on parts of the human genome. During targeted NGS reactions the sequencing reads are 
distributed to specific genomic locations which equal to higher sequencing coverage and 
accurate detection of sequence variants regardless of platform error rates. The regions that are 
targeted needs to be enriched using variable capture strategies such as hybrid capture, 
microdroplet PCR, or array capture techniques. [41] Targeted sequencing is also a more time 
and cost-effective method and the data results are considerably more manageable compared to 
whole exome sequencing. Target enrichment increases sample preparation, cost and time and 
brings the field of genomics into smaller laboratories. [42] There is only a small percentage of 
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the human genome’s sequence that is characterized and therefore only limited clinically 
valuable information can be gained from whole genome sequencing. Therefore target 
sequencing is a more cost effective option for clinical researchers to screen for mutations that 
could be relevant in the diagnosis and treatment of disease. Targeted sequencing has been 
useful in screening panels of disease-related genes and also helping to increase the 
characterization of genetic contribution to different diseases. Due to targeted sequencing 
being a cost and time effective method it is possible to use genetic testing in diagnosing 
diseases with complex genetics. [41] 
One of the disadvantages with increased throughput of NGS reactions is the read length. Most 
available sequencing platforms offer on average shorter read lengths than the Sanger 
sequencing methods, and this restricts the types of experiments that can be conducted by 
NGS. For instance shorter read lengths may not map or align back to the reference genome 
uniquely which results in the repetitive sequences of the genome being unmappable in these 
types of experiments. Another challenge is sequence alignment for regions where there is high 
diversity between the reference genome and the sequenced genome as it is in structural 
variants such as insertions and deletions. These challenges are usually solved through the use 
of longer read lengths or paired-end/mate-pair approaches. [41] Another downside is that the 
use of panel-based testing can increase the complexity of result interpretation due to an 
increase in the number of variants of uncertain significance (VUS) [43]. 
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1.5 Aims for this master thesis: 
The genetic cause of CRC is only known in the hereditary CRC syndromes accounting for 
only 5% of the CRCs. Several studies have indicated that some genes could be associated 
with CRC. The aim for this master thesis was to use a gen panel of several genes reported to 
be associated with CRC, in order to find the genetic cause for the patients’ increased risk of 
CRC. 123 genes were sequenced in 95 patients where some are known to be involved in 
hereditary CRC syndromes and some are associated with CRC development using NGS 
technologies. 
For this project the gene list was divided so that the focus was on either the 101 CRC genes or 
the 22 MMR genes. The aim for this master thesis was to analyze 101 genes which are not 
involved in the MMR system but some known to be involved in inherited CRC syndromes 
and some that have been found to be associated with CRC in GWAS or NGS studies. The 
patients in this project fulfilled the Amsterdam criteria and/or the revised Bethesda guidelines.   
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2. Material and Methods 
The equipment, kits, buffers, solutions and consumables used during this project are listed in 
table 2.1, 2.2 and 2.3. 
Table 2.1. Overview of the equipment used in this project 
Description Vendor/manufacturer ID 
Agilent 2100 Bioanalyzer Agilent Technologies Cat: G2940CA 
Automat pipette   
Benchtop microcentrifuge, 
Galaxy Mini 
VMR
TM 
 International Cat: 93000-196 
Benchtop rotator FSR20 Grant Boekel  
Biohit Eline Pro (Pipette)   
Biohit Pipette (Multichannel)   
Dynal Invitrogen Bead 
Separations 
Invitrogen  
Eppendorf Centrifuge 5810R VMR
TM 
International  
Eppendorf vortex mixer PCR 
96 Tube 
Mixmate
®
Eppendorf Cat: 5353000.014 
Geneflash Bio Imaging system SynGene  
Iprep
TM
 purification instrument Invitrogen Cat: 10000 
KMS1 minishaker vortexer IKA
®
  
Magnetic Particle Concentrator Dynal MPC
®
, Life 
Technologies 
Batch: 44/55 
Microplate Sealer ALPS
TM
 25 ThermoScientific  
Multichannel pipettes, 
Finnpippette 
ThermoScientific  
Nanodrop
® 
 ND-1000 
spectrophotometer 
ThermoScientific  
Plastic Pipette, Disposable, 
Sterile 
Sterilin  
Qubit 2.0 Fluorometer, 
Invitrogen
TM
 
Life Technologies Cat: Q32866 
Thermal Cycler 2720, Applied 
Biosystemes
®
 
Life Technologies Cat: 4359659 
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Table 2.2. Overview of kits, buffers and solutions 
Description Vendor/manufacturer ID 
Acetic acid solution 2 M  Lot: SLBH 6779V 
Elution Buffer (EB) 250 ml Qiagen Gmblt Cat: 19086 
Lot: 145046057 
Haloplex Target Enrichment 
Kit, 96 reactions 
Agilent Technologies Cat: # 5190-5534 
Lot: 0006246792 
HCl solution 0.3 M for 
Nanodrop 
  
Invitrogen
TM
 Qubit® dsDNA 
high sensitivity Assay Kit  
Life technologies  
Iprep
TM
Purelink
TM
gDNA 
Blood Kit 
Invitrogen Lot: 1603453 
NaOH 10 M  Lot: 1168043 
Tris-HCl, pH 8.0   
Tris 10 mM for Nanodrop   
 
Table 2.3. A list of the consumables used in this project 
Description Vendor/manufacturer ID 
Agencourt AMPure
®
 beads 
 
Beckman Coulter Inc Lot: 14060800 
 
E-Gel iBase
TM
 2% agarose Invitrogen Lot: B16074 
Herculase II Fusion DNA 
Polymerase 
Agilent Technologies Cat: 600677-51 
Lot: 0006212697 
High Sensitivity DNA Chips Agilent Technologies Lot: SF04BK50 
High Sensitivity DNA Reagents Agilent Technologies Lot: 1420 
Ladder 4 DNA Molecular 
Weight Marker IV (0.07-19.3 
Kb) 
 Lot: 11799634 
Nuclease Free Water   
18 
 
2.1 Workflow of methods used in this project for 123 CRC genes  
Exons including splice site regions, 5’- and 3’ UTRs for 123 genes were sequenced using 
DNA samples from 95 patients. The genes were sequenced on a Illumina HiSeq2500 
platform. The figure below lists the methods used in this study.
 
 Figure 2.1. Flowchart of the methods used in this project 
•  22 of 95 samples isolated using Iprep. Remaining 73 samples were 
previously isolated and stored in a refrigerator DNA isolation 
•  DNA concentration measured on all 95 samples using Nanodrop (ND-1000) 
and Qubit 2.0 
• Table showing the results from both measurements in appendix 6.2 
Measurement of DNA 
concentration 
•  Samples diluted with nuclease free water to 5 ng/µl Normalization of the 95 
samples 
• Verification of DNA size distribution by gel electrophoresis see 
figure 3.2 chapter 3 
• Digestion reaction with restriction enzymes 
•  Validation of Enrichment control DNA using the 2100 Bioanalyzer 
• Hybridization of digested DNA to Haloplex probes  
• Capturing, ligation, elution and amplification of target DNA 
•  Purification of the amplified target library using AMPure XP beads 
Preparation of Haloplex 
library 
• Normalization of all 95 samples to a final DNA concentration using 
Tris-HCl as dilution buffer in a 1:3 dilution ratio 
• Measurement of DNA concentration of each sample using 2100 
bioanalyzer  
•  Pooling of samples and another round of AMPure beads purification 
due to adaptor-primer product 
Quantification of the Haloplex 
library 
• Pooled samples measured on the 2100 Bioanalyzer 
• Real-time PCR for quantification of pooled samples 
•  Preparation of  samples for sequence run 
•  Sequencing of Haloplex library on Illumina Hiseq 2500 
Sequencing of the Haloplex 
library 
• Human genome hg19 used as reference genome 
• Alignment done using Burrows-Wheeler aligner 
• Base calling done with GATK Best Practices Recommendations 
• Variants annotated with ANNOVAR 
• Variant filtering using Filtus 
• Alamut used to determine functional impact of variants 
• 25 variants that might play a role in patients with FCC   
 
Analysis of sequence data 
• Validation of 6 variants with Sanger sequencing 
 Validating variants found with 
Sanger sequencing 
19 
 
2.2 Material and preparation of samples before library preparation 
The patient material used for this study was gDNA isolated from EDTA preserved whole 
blood. Samples from 95 patients that fulfilled the AC and/or the revised Bethesda guidelines 
(RBG) [44] were chosen for sequencing and these are listed in appendix 6.1. DNA had to be 
isolated for 22 of the 95 samples using the Iprep
TM
 Purelink
TM 
 gDNA blood kit from 
invitrogen with the Iprep instrument. The manual for the instrument Iprep was used as a 
procedure for the DNA isolation [45]. Two patients had two blood samples each. Sample 33 
and 46 were from one patient and samples 51 and 87 from the other. 
The DNA concentration of the samples were measured on both the spectrophotometer 
Nanodrop (ND-1000) and the spectrofluorometer Qubit 2.0 according to the manufacturer’s 
instructions [46, 47]. The Nanodrop, measured the absorbance of the DNA while Qubit 2.0 
measured the fluorescence. The reagents for both Nanodrop and Qubit are listed in table 2.4 
and 2.5.  
Table 2.4. Reagents, volume and application for Nanodrop concentration measurement of 95 DNA 
samples 
Reagent Volume Application 
HCl (hydrochloric acid) 2 µl For washing 
H2O (water) 2 µl Start-up of the 
spectrophotometer 
Tris buffer 2 µl Used as a blank 
 
Table 2.5. Reagents and volume for Qubit 2.0 concentration measurement of 95 DNA samples 
Solutions Volume 
Total solution in tubes 200 µl 
Total sample volume 2 µl 
Total buffer + fluorochrome 19,9 µl 
Volume in tubes of solution 198 µl 
Following the DNA concentration measurement, all samples were diluted with nuclease free 
water to a DNA concentration of 5 ng/µl. A table of the volumes in the dilutions can be found 
in appendix 6.2.  
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2.3 Library preparation for NGS according to Agilent Technologies 
Before the library preparation, the size distribution of the undiluted DNA samples was 
verified using gel electrophoresis to see if there had been any smearing below 2.5 kb, which 
indicates sample degradation. The samples tested were samples 1-10 because these were the 
oldest samples and also sample 86 were tested since this sample was from year 2014, so it 
could be compared with the results from samples 1-10. The ladder was diluted with nuclease 
free water in ratio 1:10. The gel was run for 30 minutes and the results can be seen in a figure 
3.2 in chapter 3.  
For the library preparation a custom made Haloplex Target enrichment kit for 96 samples was 
used. The sample preparation was executed according to the HaloPlex Target Enrichment 
System protocol for Illumina Sequencing [48]. The HaloPlex target enrichment system by 
Agilent technologies uses a capture method based on hybridization and amplification of the 
gDNA fragments, where the target DNA is first digested by different restriction enzymes to 
generate a library of gDNA restriction fragments. The digested DNA is then hybridized to the 
HaloPlex probes for target enrichment and sample indexing resulting in circularized gDNA 
fragments where sample indexes and Illumina sequencing motifs have been incorporated. The 
DNA-probe hybrids which contain biotin allow for capture with streptavidin-coated magnetic 
beads and DNA ligase is used to close gaps in the circularized DNA- probe hybrids.  
The final step is PCR amplification of the targeted fragments so that a sequencing-ready 
target enrichment sample can be produced. [48] A figure of the HaloPlex target enrichment 
workflow is shown in figure 2.2 below. 
All samples were diluted 1:3 with Tris-HCl and the concentration of each sample library was 
measured using Agilent 2100 Bioanalyzer. The concentration was used to pool equimolar 
amounts (10 ng) of each sample. The expected concentration in the final pool and three 
measurements with Bioanalyzer after pooling the samples can be seen in appendix 6.3. 
Before sequencing the library a real-time PCR was performed to quantify the pooled samples. 
The library was sequenced on the Illumina HiSeq 2500 platform. There were 123 CRC related 
genes where the exons including splice-site regions and 5’ and 3’ UTRs were sequenced for 
all the 95 patients. A list of the all the genes that were sequenced due to their involvement in 
CRC is listed in appendix 6.4.  
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Figure 2.2. Overview of workflow for HaloPlex target enrichment. Step 1: Target gDNA is digested 
by restriction enzymes into restriction fragments. Step 2: Digested DNA is hybridized to HaloPlex 
probes for target enrichment and sample indexing, giving circularized DNA fragments. Step 3: 
Capturing of DNA-probe hybrids with streptavidin-coated magnetic beads. Step 4: Amplification of 
targeted fragments by PCR producing a target-enriched sample ready to be sequenced. [49] 
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2.4 Data analysis after NGS 
After sequencing the Haloplex library the sequence data was interpreted by chief engineer, 
Jostein Johansen at BioCore NTNU. The human genome hg19 was used as a reference 
sequence and the alignment was done using the Burrows-Wheeler-Aligner [50]. In this study 
the variant calling was done according to GATK Best Practices Recommendations [51, 52] 
using GATK version 3.1 [53], including local realignment around indels, recalibration of 
quality scores and quality control of called variants. To analyze the regions targeted from the 
sequencing experiment, a list of these regions were used as additional information when 
running GATK to reduce running time of the pipeline. The variants were annotated with a 
software called ANNOVAR [54]. 
   
2.5 Interpreting sequence data 
Filtering of variants was done using FILTUS [55] which is a tool for downstream analysis 
used in high-throughput sequence projects. It was used to filter out variants with a minor 
allele frequency (MAF) >1% in the 1000 genomes database and all variants present in 
dbSNP138 to select only rare variants. The synonymous variants and variants of low quality 
were also removed. The 22 MMR genes and variants with coverage lower than 10 were also 
excluded. The MMR genes were removed because they were not the focus for this study. An 
overview of the filters used with details can be seen in table 2.6. The list of the remaining 
variants after the filtration can be found in appendix 6.5 which also includes information 
about what effect the mutation has on the protein.  
Table 2.6. Filters applied to variants in Filtus 
Name of 
function/database 
Filter Parameters Keep if missing 
Exclude genes 22 MMR genes   
Exonic Func Not equal to synonymous SNV  
1000 genomes Less than 0.01 Ticked off 
dbSNP138 Does not contain  Ticked off 
FILTER Equal to PASS  
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2.5.1 Evaluation of variants  
After the filtration of variants the software Alamut visual version 2.3 by Interactive 
biosoftware was used to determine whether or not the mutation had a damaging effect on the 
protein. The information about the effect the mutation had on the protein was predicted by 
different prediction programs which are a part of the software such as AlignGVGD, SIFT, 
MutationTaster and Polyphen-2. [56] 
The variants were colour coded according to their effect on the protein and appendix 6.5 
shows an overview of these variants. The variants with the most prominent effect on the 
protein were chosen for further research.  
 
2.6 Validation of variants with Sanger sequencing 
The Sanger sequencing was performed by the clinical lab, and only a few variants were 
validated. The Sanger sequencing was done according to procedures at the clinical lab.  
First a PCR was performed to amplify the fragments that were going to be sequenced. Then 
purification of the PCR-product was done with the reagent A’SAP. This purifying reagent 
eliminates excess primers and nucleotides enzymatically without eliminating any PCR 
product.  
The sequencing-PCR was then performed which was the process where single stranded  DNA 
was amplified. The sequencing reagents contained fluorescence labeled nucleotides which 
were attached to the end of each fragment. The sequence reaction produced fragments of 
different lengths, but the number of each fragment made was random. During the sequence 
reaction the annealing temperature was specific for each primer used, and it should be similar 
to the temperature used during the PCR-reaction and no higher than 60˚C. Sequencing was 
done in both directions to sequence all the way to the opposite primer and also because 
eventual findings could be double checked.  
After the sequence reaction another purifying step is necessary to eliminate excess 
fluorescence labeled nucleotides that were not incorporated in the actual sequence, salts and 
other charged molecules that could affect the sequencing performed with capillary 
electrophoresis. The reagent used for this was BigDye XTerminator Purification kit.  
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The instrument used for the capillary electrophoresis is the ABI PRISM 3130xl or the ABI 
PRISM 3730 Genetic Analyzer. The product from the sequence reaction is first injected 
electro kinetically into the capillaries which are filled with polymer. Then the negatively 
charged DNA migrates towards the positively charged electrode and close to this electrode the 
fragments migrate through a laser beam. When the fluorescence comes in contact with the 
light from the laser a spectrum from each of the four nucleotides is produced. There is also a 
CCD camera that detects the signals as the fragments in increasing length passes by the 
detection cell during the electrophoresis. Data collection software is used to convert the 
fluorescence signals into digital data and then to an electrogram which is processed in other 
analyze programs such as Seqscape. A figure of an electrogram can be seen below. 
Figure 2.3. The picture shows an electrogram from Sanger sequencing [57]  
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3. Results 
In this study 123 genes related to CRC in 95 patients were sequenced using NGS technology 
to discover novel variants involved in the development of CRC in high-risk individuals. The 
focus for this study was 101 CRC related genes. The results were interpreted using the NGS 
downstream analysis tool FILTUS and the software program Alamut. Some interpreted high 
risk variants were further investigated. 
 
3.1 Measurement of DNA concentration  
DNA concentrations were measured on Nanodrop ND-1000 and Qubit 2.0 to normalize all 
samples into an equal DNA concentration. The results can be seen in figure 3.1 and a table 
with the DNA concentration and the amount of DNA necessary to obtain the final DNA 
concentration of 5 ng/µL for each sample is listed in appendix 6.2.  
 
Figure 3.1. A graph displaying DNA concentrations of the 95 samples measured on both Nanodrop 
and Qubit. The blue line represents results from Nanodrop and the red line Qubit 2.0.  
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The DNA concentration measurement results showed that the sample concentration measured 
on Nanodrop was higher in some samples compared to samples measured with Qubit, and 
therefore the results from the Qubit measurement were used for normalization of the samples. 
The reason for the elevated concentration could be due to a systematic error in Nanodrop or it 
could have been because the samples were not mixed properly before measuring.  
The size distribution of undiltued DNA samples were verified with gel electrophoresis to see 
if the DNA in the samples were degraded, and the results can be seen in figure 3.2 below.  
 
Figure 3.2. The picture shows the results from a gel electrophoresis that tested samples 1-10 and 
sample 86 to verify the size distribution of DNA. The samples are in chronological order except for 
sample three which is the ladder meaning that well 4 contains sample nr. 3. 
The result from the gel electrophoresis shows that all the fragments were larger than band 9-
10 of the ladder well nr 3 in figure 3.2, and these bands were approximately 2.5 kb. This 
means that there was no smearing below 2.5 kb and therefore no degradation of the DNA in 
the samples. 
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3.2 Preparation of Haloplex library 
Before the Haloplex library could be pooled and sequenced the enrichment and the quantity of 
the enriched target DNA had to be validated in each sample. This was done by using the 2100 
Bioanalyzer and an example of an electropherogram from one of the samples can be seen in 
figure 3.3. 
 
 
Figure 3.3. Here is an example of an electropherogram from 2100 Bioanalyzer of sample 12 where the 
largest peak is the sample itself which lies between 200-600 bp. The x-axis displays the number of 
base pairs whereas the Y-axis plots the intensity of the sample. The peaks with the coloured numbers 
on top are the lowest and the upper markers of the ladder. The concentration of this sample is 7.66 
ng/µL which can be accepted since it is less than 10  ng/uL. 
The results from the Bioanalyzer measurement are listed in appendix 6.3 as well as the 
volume used to obtain equal molar amounts of each sample prior to pooling of the samples. 
The results showed that the target enrichment process was successful since the Bioanalyzer 
measurements showed that a library was obtained. The concentration of each sample 
(appendix 6.3) was acceptable since the concentration was supposed to be below 10 ng/µl. 
The expected concentration was consistent with actual concentration of the pooled samples as 
can be seen in the table.  
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The mean coverage across all samples was 258.18 and the table with mean coverage for each 
sample is listed in appendix 6.6. The standard deviation of the total coverage is 258.18 ± 
57.76. On average, 86.72 % of the target region were covered with >20 reads. The standard 
deviation of the regions covered with >20 reads is 2162 ± 42.92. The table with regions 
covered with >20 reads for each sample is listed in appendix 6.7.  
 
3.3 Interpretation of sequence data 
The result from the NGS was filtered with the downstream analysis tool FILTUS and the 
number of variants before any filters were added was 1268 unique variants in 123 genes. A 
table of the number of total variants in each patient is listed in appendix 6.8. From this table it 
can be seen that the number of variants in sample 33 and sample 46 both samples from the 
same patient, are not equal. Before filtering away the variants of low quality there were 305 
variants in 80 genes in sample 33 and 338 variants in 77 genes in sample 46. The number of 
variants after excluding the variants of low quality were 229 variants in 71 genes in sample 33 
and 228 variants in 77 genes in sample 46. The variants that differ between the samples are 
two nonframeshift insertion variants found in the BLM gene 
c.2318_2319insAGA:pS773delinsRD and c.2319_2320insCGG:pS773delinsSR and one 
nonframeshift insertion found in the MRPL3 gene c.471_472insTCT:p.A158delinsSA. All 
three variants were found in sample 46 and not in sample 33. Sample 33 had a 
nonsynonymous variant in the PSPH gene c.T549:p.D183E that was not found in sample 46. 
The number of variants in samples 51 and 87 that were also from the same patient were also 
unequal. Before the variants of low quality were excluded there were 316 variants in 78 genes 
in sample 51 and 297 variants in 78 genes in sample 87. After the low quality variants were 
excluded 217 variants in 72 genes remained in sample 51 and 218 variants in 70 genes in 
sample 87. The variants that differ between these samples are two nonframeshift insertions in 
BLM and one nonframeshift insertion in MRPL3 all three found in sample 51, which are the 
same variants found in sample 46.  
To make the number of variants more manageable and to focus only on the rare variants, 
filters were added to exclude variants with a MAF >1% which were present in the databases 
1000 genomes and dbSNP138. The other variants that were excluded were the synonymous 
variants, variants of low quality, the 22 MMR genes and the variants with coverage lower 
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than 10. The table with the details of the filters applied can be found in chapter 2 in table 2.6. 
After the filtration 1171 variants were excluded leaving 97 unique variants in 54 genes. To 
further decrease the number of variants the variants found in many patients were excluded due 
to the fact that they were thought to be more common in the population than those found only 
in a few patients. The variants that were chosen to look closer into were those found in one or 
two patients. Information about the predicted consequences of the mutation at protein level 
was determined using the Alamut software. Appendix 6.5 shows the remaining variants after 
filtration with information about the predicted effect the mutation has on the protein. As can 
be seen from the table in appendix 6.5 there were 64 unique variants in 41 genes to do further 
work with after the selection of variants. A table with number of variants found in each 
patient after the filtration is listed in appendix 6.9. The variants that are listed in appendix 6.5 
have mostly been found in one or two patients, but some variants were chosen that were found 
in up to ten patients, because these variants were in genes known to cause inherited CRC 
syndromes. The table shows that there are five types of mutations: 45 missense, 5 frameshift 
insertions, 5 nonframeshift insertions, 7 frameshift deletions and 2 nonframeshift deletions, 
and more than half of the mutations are according to Alamut damaging for the protein.  
The table in appendix 6.5 was used to select the variants to investigate further to see if these 
could be involved in the cause of CRC for the high-risk individuals. The variants that were 
selected were those predicted by Alamut to have a damaging effect on the protein, and these 
mostly included the frameshift variants but also a few missense variants. The reason why only 
a few variants were chosen and not all the variants that were according to Alamut damaging 
to the protein, was because these were thought to be the most interesting variants to further 
investigate. Usually the frameshift mutations are more damaging than missense mutations 
because they change the reading frame completely, although this is not always the case. The 
few missense variants that were decided to investigate further were chosen because some of 
them are known in the development towards CRC. The number of variants found to 
investigate further was 25 unique variants. 
Some of the variants chosen are found in genes that are known to cause hereditary CRC 
syndromes and these are listed in table 3.1. The remaining variants are found in genes 
associated with CRC and they are listed in table 3.2.  
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Table 3.1. A list of variants in genes known to cause hereditary CRC syndromes. The variants found 
to be false positive with Sanger sequencing are highlighted in red. 
Gene  Patients Nomenclature AlignGVGD SIFT MutationTaster Polyphen-2 
POLE 6,29,30 NM_006231:c.1
373A>T:p.Y458
F 
Class C0  Deleterious 
(score 0) 
Disease causing 
(P-value: 1) 
Probably 
damaging 
(Humdiv 
1.000 + 
humvar 
1.000) 
POLE 44 NM_006231:c.8
24A>T:p.D275
V 
Class C0  Deleterious 
(score 0) 
Disease causing 
(P-value:1) 
Probably 
damaging 
(Humdiv 
1.000 + 
humvar 
1.000) 
APC  14,24,46
,47,49,5
9-
61,72,95 
 
NM_001127511
:c.3086_3087ins
TCGG:p.Lys103
0Argfs*2 
 
N/A N/A N/A N/A 
BMPR1A 32 NM_004329:c.7
85T>C:p.V262
A 
 
Class C0  Tolerated 
(score 0.15) 
Disease causing 
(P-value: 1) 
Possibly 
damaging 
(Humdiv 
0.923 + 
humvar 
0.884) 
GREM1 30,31,60 NM_013372:c.1
96_197insT:p.T
hr66Ilefs*35 
N/A N/A N/A N/A 
PTEN 35,48 NM_000314:c.3
77C>T:p.A126
V 
Class C0  Tolerated 
(score 0.29) 
Disease causing 
(P-value: 1) 
Probably 
damaging 
(Humdiv 
1.000 + 
humvar 
0.998) 
STK11 60 NM_000455:c.4
59_460insAGA:
p.Ala153_His15
4insArg 
N/A N/A N/A N/A 
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Table 3.2. Variants in genes associated with CRC   
Gene  Patients Nomenclature AlignGVGD SIFT MutationTaster Polyphen-2 
AKT1 32 NM_001014431
:c.206G>C:p.R6
9P 
Class C35 Deleterious 
(score 0.01) 
Disease causing 
(P-value: 0.995) 
Possibly damaging 
(Humdiv 0.792 + 
humvar 0.667) 
AKT1 46 NM_001014431
:c.520C>T:p.R1
74C 
Class C0 Deleterious 
(score 0) 
Disease causing 
(P-Value: 1) 
Possibly damaging 
(Humdiv 0.900 + 
humvar 0.800) 
BUB1 49,65 NM_ 004336.4: 
c. 
447_448insTCT 
p.Glu149_Thr15
0insSer 
N/A N/A N/A N/A 
BUB1B 11,45,50
,62 
NM_001211:c.2
252_2253insAG
A:p.Pro751_Lys
752insAsp 
N/A N/A N/A N/A 
BUB1B 11,45,62 NM_001211:c2
253_2254insCG
G:p.Pro751_Lys
752insArg 
N/A N/A N/A N/A 
DCC 46 NM_005215:c.1
664_1665insCG
AGAT:p.Asn55
5_Gly556insGlu
Ile 
N/A N/A N/A N/A 
FAM166A 16,22,52 NM_001001710
:c.751_752del:p.
Leu251Valfs*2 
N/A N/A N/A N/A 
FANCM 17,28 NM_020937:c.5
607_5608del:p.
Glu1870Aspfs*
4 
N/A N/A N/A N/A 
KIF23 71 NM_138555.2 
c.610_618del 
p.Phe204_Lys20
6del 
N/A N/A N/A N/A 
LAMB4 78 NM_007356:c.5
265delA:p.Lys1
755Asnfs*11 
N/A N/A N/A N/A 
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Gene Patients Nomenclature AlignGVGD SIFT MutationTaster Polyphen-2 
LAMC1 14,51,71
,79 
NM_002293:c.4
579_4580del:p.
Leu1527Glyfs*
7 
N/A N/A N/A N/A 
MAML3 3,37 NM_018717:c.1
513_1514del:p.
Gln505Alafs*21 
N/A N/A N/A N/A 
MAML3 3,18,34,
41,52,59
,64,77,9
0 
NM_018717:c.1
506delG:p.Gln5
02Hisfs*20 
N/A N/A N/A N/A 
NOTCH3 34 NM_000435:c.3
733_3734insT:p
.Thr1245Ilefs*2
0 
N/A N/A N/A N/A 
PIK3CA 38 NM_006218:c.1
07_108insAGA
T:p.Cys36fs* 
N/A N/A N/A N/A 
PPP1CB 72 NM_002709:c.4
69_470insAGA
TC:p.Cys157* 
N/A N/A N/A N/A 
RAI1 35,48 NM_030665:c.8
38_843del:p.280
_281del 
N/A N/A N/A N/A 
TBX3 66 NM_016569.3. 
c.1893del 
p.Asn632Thrfs*
257 
N/A N/A N/A N/A 
 
3.4 Validation of variants found with Sanger sequencing 
The variants validated were in genes included in diagnostic gene testing at the Medical 
Genetic Laboratory at St. Olavs Hospital. Thus primers for these genes were available, and 
included the two POLE variants, the PTEN variant, the BMPR1A variant, the STK11 variant 
and the APC variant. The results from the sequencing showed that the APC variant 
c.3086_3087insTCGG and the STK11 variant c.459_460insAGA were both false positive. 
The PTEN variant c.377C>T, the POLE variants c.1373A>T and c.824A>T and the BMPR1A 
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variant c.785T>C were confirmed to be true variants. An alignment of POLE with the 
position of the mutations marked can be seen below in figure 3.4.  
Figure 3.4. Overview of an alignment of POLE and POLD1 in several species. The two positions of 
the variants identified in this study p.Asp275Val and p.Tyr458Phe are marked with a black square and 
red star. The blue boxes show conserved positions with red background for completely conserved 
positions. Blue horizontal lines show the exonuclease domains and catalytic residues are shown with 
red squares within the exonuclease domains. [20] 
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4. Discussion 
The purpose of this study was to detect novel variants in genes that are both well-known and 
not so well-known to predispose to CRC in patients that have a higher increased risk for 
developing CRC than the general population. 
 
4.1 Variants found in genes known to predispose to inherited CRC 
syndromes 
4.1.1 The variants POLE c.1373A>T and c.824A>T 
The Pole variant c.1373A>T:p.Tyr458Phe that was found in three related individuals during 
this study was also found in an exome project of one large family by Hansen et al.[20] and it 
was found to be highly penetrant [20].  
In the study by Hansen et al. [20] it was found that the tyrosine in this position is completely 
conserved between species and that the position is important for exonuclease activity. When 
the same position in orthologs was mutated to phenylalanine, alanine or histidine the 
exonuclease activity was significantly reduced, resulting in reduced fidelity of DNA 
replication and an increased mutation rate. The POLE variant c.1373A>T which was 
validated with Sanger sequencing seemed to be the cause of CRC in the family in the study by 
Hansen et al.[20]  
The mutation in the POLE variant that causes the substitution from tyrosine to phenylalanine 
was in this study predicted to be damaging at protein level by all the prediction programs in 
Alamut. The alignment in figure 3.4 in chapter 3 shows that the mutation lies in a catalytic 
residue and a highly conserved region. The POLE variant identified in the samples from the 
patients in this study were from the same family as the one studied in Hansen et al [20]. 
Palles et al. [17] also found a variant in POLE and POLD1 which was heterozygous germline 
variants that were not found in any controls. This missense variant in POLE was a 
p.Leu424Val which was detected in a family with adenomas and CRC, and it appeared to 
have a dominant inheritance with a high penetrance as well. The change from leucine to a 
valine was according to the study predicted to have severe functional consequences for the 
protein function, including that the amino acid itself was highly conserved. By mapping the 
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mutation found in POLE and POLD1 onto the structure of yeast DNA polymerase it was 
found that they pack together at the interface between two helices which form the base of the 
exonuclease active site. This means that mutations of POLE 424 and POLD1 478 will alter 
the packing of the helices and thereby distort the active site which will then affect the 
nuclease activity. [17]  
The other variant in POLE c.824A>T:p.Asp275Val that was found in this study was identified 
in one patient and has not been found in any other studies. The prediction programs in Alamut 
predicted the mutation causing the substitution from Aspartic acid to Valine to be damaging at 
protein level. From the alignment in figure 3.4 it can be seen that this mutation as well lies in 
a catalytic residue and a highly conserved region. This suggests that both mutations identified 
in POLE during this study might affect the exonuclease acitivity of the protein. These findings 
and the findings in the studies described above strongly indicate that these variants are 
involved in CRC development.  
 
4.1.2 The variant BMPR1A c.785T>C 
The BMPR1A variant c.785T>C:p.Val262Ala identified in this study was found in one 
individual and it has not been reported earlier. The substitution from Valine to Alanine was 
predicted to be damaging at protein level by three of the four prediction programs in Alamut. 
According to this software the mutation lies in a highly conserved region indicating that 
alterations may affect the protein activity. On the other hand because one of the prediction 
programs (SIFT) in Alamut predicted the mutation to be tolerated, it is not definite that it has 
a damaging effect on the protein. Due to this gene’s involvement in CRC and because 
mutations in this gene causes JPS there is a strong possibility that the variant found in this 
study might also be involved in predisposition to CRC.  
 
4.1.3 The variant PTEN c.377C>T 
The PTEN c.377C>T:p.Ala126Val variant found during this study was found in two patients 
and have not been reported earlier. In a study by Tan et al. [58] a mutation in PTEN was 
found in the same codon as the variant identified in this study. The variant identified by Tan 
et al. [58] was a missense variant c.376G>C :p.Ala126Pro which was found to be pathogenic. 
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This indicates that the PTEN variant c.377C>T might also be pathogenic because it is located 
in the same codon. The difference between valine and proline is that proline is very unique 
because it is the only amino acid where the side chain is connected to the protein backbone 
twice. This makes proline an imino acid in its isolated form because it contains a NH
2+
 group 
instead of a NH
3+
 group. Due to this difference proline is unable to occupy several of the 
main-chain conformations which are easily adopted by the other amino acids. Proline often 
does not substitute well due to its unique properties.   
Three of four prediction programs in Alamut predicted the variant identified in PTEN to be 
damaging at protein level. The mutation was found to lie in a highly conserved region which 
indicates that the mutation may affect protein activity. It is not definite that the protein 
activity will be affected due to one prediction program (SIFT) classifying the mutation as 
tolerated. Since germline mutations in PTEN are the cause of both CS and BRRS, it is likely 
that the variant identified in this project could be involved in the predisposition to CRC.  
 
4.1.4 The variant GREM1 c.196_197insT 
The variant GREM1 c.196_197insT:p.Thr66Ilefs was identified in three individuals and the 
variant has not been reported earlier. The Gremlin 1, DAN family BMP antagonist (GREM1; 
MIM # 603054) encodes a member of the bone morphogenic protein (BMP) antagonist family 
and they contain cystine knots and form homo-and heterodimers. The gene belongs to a 
subfamily of BMP anatagonists the CAN (Cerberus and dan) and is characterized by a C-
terminal cystine knot with an eight-membered ring. GREM1 might be involved in regulation 
of organogenesis, body patterning and tissue differentiation. [59] 
In a study by Jaeger et al. [60] there was identified a duplication across the 3` end of the 
SCG5 gene and a region upstream of the GREM1 locus in Ashkenazi Jewish families with 
hereditary mixed polyposis syndrome (HMPS). This syndrome has a clear autosomal 
dominant inheritance of several different types of colorectal polyps and the affected 
individuals have a high occurrence of colorectal carcinoma. The duplication contains 
enhancer elements where some interact with the GREM1 promoter and are able to force gene 
expression in vitro. The mutation identified is associated with increased allele-specific 
GREM1 expression and GREM1 expression can cause reduced BMP activity which is also 
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the mechanism behind tumorigenesis in JPS. The mutation is a polymorphism rs4779584. 
[60]  
In another study executed by Yang et al. [61] 12 case-control studies involving several cases 
of CRC and healthy controls the rs4779584 polymorphism was investigated to see if it was 
associated with CRC. The results from the study showed that the GREM1-SCG5 rs4779584 
polymorphisms were associated with CRC in all the genetic models that were studied in the 
meta-analysis of the 12 case-control studies. The findings in the study suggest that the 
polymorphisms might give an increased risk for developing CRC. [61] 
Due to the mutation in GREM1 being a frameshift mutation it is almost always damaging at 
protein level because it causes a shift in the reading frame, and this might be associated with 
decreased GREM1 expression. The findings in these studies indicate that the GREM1 gene 
might be involved in the predisposition to CRC. This means that the variant found during this 
study could also be involved in CRC development.  
 
4.2 Variants associated with CRC found in GWAS and NGS  
4.2.1 Variants found in FAM166A, MAML3, PPP1CB, NOTCH3, LAMB4, FANCM 
and RAI1 
The variant identified in this study in FAM166A c.751_752del:pLeu251Valfs was found in 
three individuals, LAMB4 c.5265delA:p.Lys1755Asnfs was found in one individual and also 
found in the study by Smith et al. [62]. MAML3 c.1513_1514del:p.Gln505Alafs was 
identified in two individuals and MAML3 c.1506delG:p.Gln502Hisfs was found in nine 
patients. FANCM c.5607_5608del:p.Glu1870Aspfs was found in two patients. The variant 
found in RAI1 c.867_872del p.Gln290_Gln291del was identified in two patients. NOTCH3 
c.3733_3734insT:p.Thr1245Ilefs and PPP1CB c.469_470insAGATC:p.Cys157 were both 
identified in one patient. None of the variants except the variant identified in LAMB4 have 
been previously reported.  
In the study by Smith et al. [62]  1138 genes in 50 sporadic patients with advanced CRC were 
exome resequenced to find rare or novel germline mutations that were likely to play a role in 
colorectal tumorigenesis. The study identified germline mutations in the genes FAM166A, 
MAML3 (MIM # 608991), PPP1CB (MIM # 600590), NOTCH3 (MIM # 600276), LAMB4, 
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FANCM (MIM # 609644) and RAI1 (MIM #607642). The variants in the genes FAM166A, 
MAML3, PPP1CB and RAI1 were not described further in the study, but according to the 
study they are likely to play a role in CRC. The germline mutation found in NOTCH3 by 
Smith et al. [62] was identified in a patient diagnosed with CRC at the age of 29. This patient 
had no family history of CRC. NOTCH3 has recently been found to modulate the tumorigenic 
properties of CRC cell, but because nonsynonymous mutations are associated with cereberal 
autosomal dominant arteriopathy with subcortical infacts and leukoencephalopathy 
(CADASIL), further studies are needed to determine if loss of protein function in this gene is 
associated with CRC. The mutation identified in LAMB4 was found in a patient diagnosed 
with CRC at the age of 68 and it showed somatic loss of the wild-type LAMB4 allele. The 
patient diagnosed with this variant did not have a history of other cancers but had a 
grandfather that died of CRC at the age of 75. Although this mutation was identified in a CRC 
patient it was concluded in the study that LAMB4 was not likely to play a significant role in 
predisposition to CRC. In FANCM both germline and somatic mutations were identified and 
the mutations were found in two unrelated patients with CRC. The mutations were consistent 
with the two-hit hypothesis and the germline mutation was also identified in one control 
sample. [62] 
There is little information available about these genes and their role in CRC, therefore further 
research is necessary to determine if the variants identified in this study are involved in 
predisposition to CRC.  
 
4.2.2 The variants found in BUB1B and DCC   
The variants identified in BUB1B c.2252_2253insAGA:p.Pro751_Lys752insAsp and 
c.2253_2254insCGG:p.Pro751_Lys752insArg might be the same variant and 
c.2253_2254insCGG might be a false positive. The variant in BUB1B was found in seven 
patients. The Variant in DCC c.1664_1665insCGAGAT:p.Asn555_Gly556insGluIle was 
identified in one patient. These variants have not been reported earlier.  
The DCC (MIM #120470) gene with the cytogenetic location 18q21.3 encodes the protein 
netrin 1 receptor which functions as a tumor suppressor and is often mutated or 
downregulated in CRC and esophageal carcinoma [63]. In a study by Popat et al. [64] it was 
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found that patients with CRC with chromosome 18q allelic imbalance or loss of DCC 
expression have a poorer prognosis [64].   
The BUB1B (MIM #602860) gene may cause CIN in CRC [65].  In a study by Cahill et al. 
[66] somatic mutations were identified in 2 out of 19 CRC cell lines and these were not 
identified in 40 normal alleles [66].  
There is little information available about BUB1B and its function in CRC, therefore further 
studies are necessary to determine the function of the variant identified in this gene in CRC 
predisposition. DCC seems to play a role in CRC predisposition indicating that the variant 
identified in this gene during this study might play a role CRC. The definite function of the 
DCC variant in CRC is not clear, thus further research is necessary to determine this.    
 
4.2.3 Variants found in AKT1, BUB1, KIF23, LAMC1, PIK3CA and TBX3 
The variants identified in AKT1 c.206G>C:p.Arg69Pro and c.520C>T:p.Arg174Cys, KIF23 
c.610_618del:p.Phe204_Lys206del, PIK3CA c.107_108insAGAT:p.Cys36fs and TBX3 
c.1893del:p.Asn632Thrfs were each found in one individual. The variant identified in BUB1 
c.447_448insTCT:p.Glu149_Thr150insSer was found in two patients and the variant 
identified in LAMC1 c. 4579_4580del:p.Leu1527Glyfs was found in four patients. Neither of 
the variants have been previously reported.  
Mutations in these genes have in some studies been found to be associated with CRC and 
these will be briefly described below.  
A somatic mutation in AKT1 (MIM #164730) was identified in a study by Carpten et al. [67] 
in human breast, ovarian and colorectal cancers. The study showed that the mutation 
identified activates AKT1 through pathological localization to the plasma membrane, 
stimulates downstream signaling, transforms cells and induces leukemia in mice. This process 
suggests that AKT1 has a direct role in human cancer, and adds to known genetic changes that 
promote oncogenesis through the phosphatidylinositol-3-OH kinase/AKT pathway. [67] In a 
study by Orloff et al. [68] mutations in AKT1 were found to be associated with CS. 
According to the results 91 probands with CS negative for mutations in the known disease-
causing genes, two were found to have germline mutations in AKT1. The effect of the 
mutations was increased P-Thr308-AKT and increased cellular PIP3. [68] 
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The BUB1 (MIM # 602452) locus was in a study by Jaffrey et al. [69] studied in 32 CRC 
patients and in 20 non-small cell lung cancer (NSCLC) primary tumours with a panel of seven 
microsatellite repeats for 2q, two CA repeats in BUB1 and gene mutation analysis. In 20 of 32 
colorectal primary tumors the 2q locus was quite unstable. Results also showed 14.5% of 
CRC patients with instability within BUB1. Jaffery et al. [69] concluded that in this study 2q 
and BUB1 allelic instability in CRC were shown, but mutations in BUB1 are rare causes of 
chromosomal instability in CRC or NSCLC. [69] In another study De Voer et al. [70] 
identified haploinsufficiency or heterozygous mutations in the spindle assembly checkpoint 
genes BUB1 and BUB3 with genome-wide and targeted copy number and mutation analysis. 
208 patients with familial or early onset CRC were analyzed and they also had variegated 
aneuploidies in multiple tissues and variable dysmorphic features. The discoveries in this 
study indicated that mutations in both BUB1 and BUB3 cause mosaic variegated aneuploidy 
which increases the risk of CRC at a young age. [70]     
A missense variant in KIF23 (MIM # 605064) was identified in the study by DeRycke et al. 
[7] where 40 cases from 16 familial CRC families were germline exome sequenced. It was 
found to be a rare variant and it was only observed in the ESP database of European 
Americans. The variant was validated and replicated and is located in previously reported 
CRC linkage regions. [7] 
In a study by Peters et al. [71] a polymorphism in LAMC1 (MIM #150290) rs10911251 and 
in TBX3 (MIM # 601621) rs59336 were identified in GWAS.  Both of the polymorphisms 
were associated with CRC. The polymorphism in LAMC1 is located in a region that is highly 
evolutionary conserved. The SNP is also close to the promoter which indicates that it might 
influence gene transcription. The study strongly suggested that this polymorphism is involved 
in development of CRC. TBX3 has also been found to be over expressed in several cancers 
such as in pancreatic-, liver-, breast cancer and melanoma. TBX3 was in liver cancer observed 
as a downstream target of the Wnt/β-catenin pathway, mediating β-catenin activities on cell 
proliferation and survival. This pathway is known to play an important role in CRC 
development. [71] The study by Whiffin et al. [72] confirmed the LAMC1 SNP’s association 
to CRC in their meta-analysis of five GWAS. [72]  
In a study by Shan et al. [73] TBX3 expression was found to be higher in CRC tissues than in 
normal tissues. The study suggested that TBX3 might be involved in CRC development by 
participating in the Epithelial-Transition Mesenchymal (EMT), and EMT have been suggested 
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to be involved in regulation of cancer metastasis. TBX3 might also have the potential to be an 
effective prognostic predictor for CRC patients. [73] 
Somatic mutations in PIK3CA (MIM # 171834) in 74 tumors out of 199 CRC were identified 
in a study by Samuels et al. [74]. The location of the mutations in PIK3CA indicated that they 
are likely to increase kinase activity. The results from the study suggest that PIK3CA when 
mutated is likely to function as an oncogene in human cancers. [74] In the study by Orloff et 
al. [68] 8 probands with CS who were negative for mutations in the known causing CS genes 
were found to have heterozygous germline mutations in the PIK3CA gene. Functional assays 
showed that the result of these mutations were upregulation of AKT1 phosphorylated at 
thr308 and increased cellular PIP3. [68].  
The variants identified in AKT1 lies according to Alamut in highly conserved regions 
meaning that the mutations will have an effect on protein activity. The variants identified in 
the genes LAMC1, PIK3CA and TBX3 are frameshift mutations which means that they will 
also have an effect on the protein activity. The BUB1 and KIF23 variants are nonframeshift 
mutations and these might have an effect on the protein activity as well, although not as major 
as a frameshift mutation because they do not cause a shift in the reading frame. There is not 
sufficient enough literature available for these genes and their function in CRC to determine if 
the variants identified in this study are involved in predisposition to CRC. To determine the 
function of these genes in CRC predisposition further functional studies are needed. 
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4.3 Targeted NGS Sequencing  
Targeted sequencing is a technique that is very useful in cancer research due to its ability to 
focus on specific genes and also the entire human genome. The opportunity to use genetic 
testing in the diagnosis of diseases with complex genetics is very valuable and in cancer 
research the possibility to sequence only parts of the genome and focus on specific genes is 
extremely helpful in the research process. [41] Targeted sequencing also enables sequencing 
of all CRC related genes simultaneously which increases the time it takes to assess a patient.  
In this study there were detected 1268 unique variants using the Haloplex targeted NGS 
method where 25 of these were chosen to further investigate based on the criteria that the 
mutations were damaging at protein level. From the 25 variants two variants, one in APC and 
one in STK11, were found to be false positive by Sanger sequencing. The reason for this 
might be because during processing of NGS data it is not possible to remove the PCR 
duplicates because enzymes are used to digest the DNA. Thus removal of PCR duplicates 
would result in removal of parts of the PCR product. Due to only 6 variants being validated 
with Sanger sequencing there is a possibility that there are additional false positive variants. 
There were also found unequal number of variants in the samples that were from the same 
patients. The samples 33 and 46 that were from the same patient had a variant similarity of 
about 92% and the samples 51 and 87 had a variant similarity of about 95-97%. The possible 
explanation for the discrepancy in variants between the samples is that the variants might 
have been false positive and that the reason for their appearance might also be because PCR 
duplicates are impossible to remove. Another possible false positive variant is the second 
framshift insertion variant detected in BUB1B c.2253_2254insCGG because this variant seem 
to be in the same region as the other BUB1B variant with the only difference being one 
nucleotide. The 10 false positive variants detected in this study are an indication that the 
reproducibility of this method is not 100%. There is no guarantee that there are false negatives 
among the variants identified, and due to the selection criteria in this study to only focus on 
the frameshift variants and some missense variants known in CRC there is a possibility that 
highly penetrant variants have been lost.  
Even though false positive variants were detected the rate of these variants are not high and 
because the two POLE variants, the BMPR1A and PTEN variant detected were most likely to 
be involved in CRC development and that several other variants detected were likely to be 
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involved in CRC such as those found in the genes PIK3CA, AKT1, DCC, GREM1 among 
others, targeted sequencing seems to be a reliable method to use in cancer research.  
 
4.4 Conclusion and prospective work 
The purpose of this study was to identify novel variants in patients with an increased risk of 
developing CRC, using targeted NGS sequencing in genes known to be involved in hereditary 
CRC syndromes and in genes associated with CRC. Many variants were identified and among 
these two novel variants in POLE c.1373A>T and c.824A>T, the variant in BMPR1A 
c.785T>C and the variant in PTEN c.377C>T were found to be involved in CRC 
development. This proves that targeted sequencing seems to be a useful tool in identifying 
novel variants in CRC, but because not all variants were validated there is no guarantee that 
there are other false positive variants among those discovered in this study. There is also a 
possibility of false negative variants and loss of highly penetrant variants due to not all 
variants being further investigated. Prospective work will therefore be to validate the variants 
found in the genes AKT1, BUB1, BUB1B, DCC, FAM166A, FANCM, GREM1, KIF23, 
LAMB4, LAMC1, MAML3, NOTCH3, PIK3CA, PPP1CB, RAI1 and TBX3. These genes 
have all been associated with CRC but there is not sufficient information to state that they are 
involved in CRC and therefore further functional studies are needed. The variants identified in 
this study that were not further described mainly the missense variants, need further 
functional studies to determine their role in CRC development.    
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6. Appendix 
6.1 Patients fulfilling the Amsterdam criteria and/or the revised Bethesda 
guidelines 
 
Patient nr. AC RBG 
1 Positive Positive 
2 Positive Positive 
3 Positive Positive 
4 Positive Positive 
5 Negative Positive 
6 Negative Positive 
7 Positive Positive 
8 Negative Positive 
9 Positive Positive 
10 Positive Positive 
11 Positive Positive 
12 Positive Positive 
13 Positive Positive 
14 Positive Positive 
15 Positive Positive 
16 Negative Negative 
17 Positive Positive 
18 Positive Positive 
19 Positive Positive 
20 Positive Positive 
21 Positive Positive 
22 Positive Positive 
23 Positive Positive 
24 Positive Positive 
25 Positive Positive 
26 Positive Positive 
27 Positive Positive 
28 Positive Positive 
29 Positive Positive 
30 Positive Positive 
31 Positive Positive 
32 Positive Positive 
33 Positive Positive 
34 Positive Positive 
35 Positive Positive 
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Patient nr. AC RBG 
36 Positive Positive 
37 Positive Positive 
38 Positive Positive 
39 Negative Positive 
40 Negative Positive 
41 Positive Positive 
42 Positive Positive 
43 Positive Positive 
44 Positive Positive 
45 Positive Positive 
46 Positive Positive 
47 Negative Positive 
48 Positive Positive 
49 Negative Positive 
50 Negative Negative 
51 Positive Positive 
51 Positive Positive 
52 Negative Positive 
53 Positive Positive 
54 Positive Positive 
55 Positive Positive 
56 Positive Positive 
57 Positive Positive 
59 Positive Positive 
60 Positive Positive 
62 Positive Positive 
63 Positive Positive 
64 Positive Positive 
65 Positive Positive 
66 Positive Positive 
67 Positive Positive 
68 Positive Positive 
69 Negative Negative 
70 Positive Positive 
71 Positive Positive 
72 Positive Positive 
73 Positive Positive 
74 Positive Positive 
75 Negative Positive 
76 Negative Negative 
77 Positive Positive 
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Patient nr. AC RBG 
78 Positive Positive 
79 Positive Positive 
80 Positive Positive 
81 Negative Negative 
82 Negative Positive 
83 Negative Positive 
84 Negative Positive 
85 Positive Positive 
86 Positive Positive 
87 Positive  
88 Negative  
89 Negative  
90 Negative  
91 Negative  
92 Negative  
93 Negative  
94 Positive  
95 Positive  
96 Positive  
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6.2 Overview of DNA concentration measurement for ND-1000 and Qubit 
 
 Concentration 
Nanodrop 
Concentration 
Qubit 
Sample volume Dilution volume 
Sample nr. ng/μL ng/μL μL µl 
1 21,54 28,9 7,8 37,2 
2 31,59 43,4 5,2 39,8 
3 13,92 27,0 8,3 36,7 
4 51,48 51,0 4,4 40,6 
5 30,43 32,9 6,8 38,2 
6 76,41 49,3 4,6 40,4 
7 28,07 37,0 6,1 38,9 
8 20,10 28,4 7,9 37,1 
9 8,89 8,2 27,3 17,7 
10 22,46 27,2 8,3 36,7 
11 24,44 22,7 9,9 35,1 
12 83,29 54,0 4,2 40,8 
13 46,70 50,0 4,5 40,5 
14 31,67 36,2 6,2 38,8 
15 22,37 19,6 11,5 33,5 
16 31,16 32,3 7,0 38,0 
17 36,01 50,0 4,5 40,5 
18 41,41 41,8 5,4 39,6 
19 52,78 45,2 5,0 40,0 
20 27,03 30,8 7,3 37,7 
21 31,30 28,8 7,8 37,2 
22 29,10 38,7 5,8 39,2 
23 29,49 26,6 8,5 36,5 
24 33,99 36,2 6,2 38,8 
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 Concentration 
Nanodrop 
Concentration 
Qubit 
Sample volume Dilution volume 
Sample nr. ng/μL ng/μL μL µL 
25 33,02 36,3 6,2 38,8 
26 23,58 22,2 10,1 34,9 
27 39,30 44,1 5,1 39,9 
28 29,73 28,3 8,0 37,0 
29 23,19 22,8 9,9 35,1 
30 29,66 26,2 8,6 36,4 
31 31,22 29,7 7,6 37,4 
32 43,44 43,2 5,2 39,8 
33 22,73 25,5 8,8 36,2 
34 37,22 41,1 5,5 39,5 
35 28,28 15,3 14,7 30,3 
36 31,79 43,1 5,2 39,8 
37 48,29 30,0 7,5 37,5 
38 43,29 14,2 15,8 29,2 
39 59,52 37,8 6,0 39,0 
40 29,63 19,8 11,4 33,6 
41 23,53 20,8 10,8 34,2 
42 26,12 22,8 9,9 35,1 
43 39,51 17,3 13,0 32,0 
44 71,92 27,9 8,1 36,9 
45 27,06 47,3 4,8 40,2 
46 53,19 30,2 7,5 37,5 
47 19,40 25,7 8,8 36,2 
48 25,59 31,4 7,2 37,8 
49 32,73 45,2 5,0 40,0 
50 28,12 27,8 8,1 36,9 
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 Concentration 
Nanodrop 
Concentration 
Qubit 
Sample volume Dilution volume 
Sample nr. ng/μL ng/μL μL µL 
51 98,33 23,1 9,7 35,3 
52 52,57 27,6 8,2 36,8 
53 32,06 29,2 7,7 37,3 
54 39,64 21,8 10,3 34,7 
55 54,57 43,3 5,2 39,8 
56 46,12 46,2 4,9 40,1 
57 22,72 11,6 19,4 25,6 
58 CONTROL CONTROL CONTROL CONTROL 
59 74,04 48,6 4,6 40,4 
60 31,16 35,0 6,4 38,6 
61 55,81 56,0 4,0 41,0 
62 36,77 51,0 4,4 40,6 
63 28,35 32,3 7,0 38,0 
64 55,30 38,7 5,8 39,2 
65 31,53 38,7 5,8 39,2 
66 49,70 35,5 6,3 38,7 
67 48,63 46,1 4,9 40,1 
68 38,00 36,4 6,2 38,8 
69 62,23 42,3 5,3 39,7 
70 43,86 39,7 5,7 39,3 
71 51,78 40,3 5,6 39,4 
72 21,75 22,6 10,0 35,0 
73 13,54 17,1 13,2 31,8 
74 24,29 33,1 6,8 38,2 
75 83,05 55,0 4,1 40,9 
76 55,39 51,0 4,4 40,6 
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 Concentration 
Nanodrop 
Concentration 
Qubit 
Sample volume Dilution volume 
Sample nr. ng/μL ng/μL μL µL 
77 67,96 56,0 4,0 41,0 
78 64,76 59,0 3,8 41,2 
79 27,42 21,1 10,7 34,3 
80 58,20 54,0 4,2 40,8 
81 110,08 58,0 3,9 41,1 
82 74,62 53,0 4,2 40,8 
83 75,64 46,4 4,8 40,2 
84 42,41 40,0 5,6 39,4 
85 110,38 112,0 2,0 43,0 
86 32,51 29,4 7,7 37,3 
87 56,91 51,0 4,4 40,6 
88 99,49 40,9 5,5 39,5 
89 35,64 32,0 7,0 38,0 
90 74,65 42,8 5,3 39,7 
91 57,37 40,2 5,6 39,4 
92 84,39 65,4 3,4 41,6 
93 62,71 49,5 4,5 40,5 
94 40,19 39,7 5,7 39,3 
95 46,75 32,6 6,9 38,1 
96 56,14 27,2 8,3 36,7 
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6.3 Bioanalyzer results before and after pooling of samples  
The table presents results from validation of enrichment and quantity of enriched target DNA for each 
sample measured on 2100 Bioanalyzer. The table also shows the volume of each sample to obtain 
equimolar concentration prior to pooling. The expected- and the actual concentration in the pool can 
also be seen.  
 Sample nr Concentration 
(ng/µl) 
Volume for equimolar 
concentration 
Chip 1 1 4,53 2,21 
 2 5,56 1,80 
 3 3,18 3,14 
 4 4,28 2,34 
 5 4,45 2,25 
 6 9,42 1,06 
 7 4,55 2,20 
 8 1,08 9,26 
 9 5,06 1,98 
 10 2,55 3,92 
 11 3,70 2,70 
Chip 2 12 7,66 1,31 
 13 3,40 2,94 
 14 3,42 2,92 
 15 2,58 3,88 
 16 3,34 2,99 
 17 5,32 1,88 
 18 5,93 1,69 
 19 3,17 3,15 
 20 4,03 2,48 
 21 2,24 4,46 
 22 4,11 2,43 
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 Sample nr Concentration 
(ng/µl) 
Volume for equimolar 
concentration 
Chip 3 23 5,55 1,80 
 24 3,89 2,57 
 25 3,17 3,15 
 26 2,54 3,94 
 27 2,23 4,48 
 28 3,24 3,09 
 29 3,16 3,16 
 30 3,62 2,76 
 31 5,19 1,93 
 32 5,76 1,74 
 33 1,61 6,21 
Chip 4 34 4,31 2,32 
 35 4,30 2,33 
 36 2,44 4,10 
 37 4,67 2,14 
 38 5,16 1,94 
 39 2,84 3,52 
 40 3,90 2,56 
 41 3,31 3,02 
 42 4,22 2,37 
 43 7,30 1,37 
 44 4,26 2,35 
Chip 5 45 2,76 3,62 
 46 3,94 2,54 
 47 4,09 2,44 
 48 4,99 2,00 
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 Sample nr Concentration 
(ng/µl) 
Volume for equimolar 
concentration 
 49 3,29 3,04 
 50 4,09 2,44 
 51 4,72 2,12 
 52 4,84 2,07 
 53 4,44 2,25 
 54 3,53 2,83 
 55 5,02 1,99 
Chip 6 56 6,40 1,56 
 57 4,01 2,49 
CONTROL 58 3,69 2,71 
 59 6,63 1,51 
 60 3,17 3,15 
 61 3,95 2,53 
 62 2,74 3,65 
 63 3,26 3,07 
 64 5,27 1,90 
 65 4,68 2,14 
 66 5,94 1,68 
Chip 7 67 1,30 7,69 
 68 3,99 2,51 
 69 4,60 2,17 
 70 5,02 1,99 
 71 4,22 2,37 
 72 2,98 3,36 
 73 2,4 4,17 
 74 3,23 3,10 
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 Sample nr Concentration 
(ng/µl) 
Volume for equimolar 
concentration 
 75 3,64 2,75 
 76 5,96 1,68 
 77 3,28 3,05 
Chip 8 78 3,97 2,52 
 79 3,67 2,72 
 80 4,40 2,27 
 81 6,86 1,46 
 82 3,43 2,92 
 83 5,45 1,83 
 84 3,48 2,87 
 85 2,77 3,61 
 86 2,30 4,35 
 87 3,55 2,82 
 88 3,78 2,65 
Chip 9 89 4,02 2,49 
 90 4,29 2,33 
 91 6,81 1,47 
 92 2,78 3,60 
 93 3,85 2,60 
 94 4,26 2,35 
 95 3,55 2,82 
 96 3,01 3,32 
 Sum  265,41 
 ng in Pool Expected 
concentration of 
pool ng/µl 
 
 950 3,58  
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 Measurements 
Pooled 
samples 
Actual 
concentration  of 
pool   
ng/µl 
 
 1 3,93  
 2 3,62  
 3 4,01  
 
 
 
  
63 
 
6.4 Overview of the 123 genes, the MMR genes are highlighted in red  
 
Gene References Association with 
syndrome 
Comment 
ACVRL1    
AKR1C4 (Gylfe et al., 2013)[34] FCC  
AKT1 MIM164730 CS  
APC MIM611731  Velkjent predisposisjons gen 
ATM    
AURKA MIM603072   
AXIN1  Finner ingen bevis DeRyke[7] mener kjent gen 
AXIN2 MIM604025 OCCS  
BAX MIM600040   
BCLAF1    
BGLAP    
BLM MIM604610 BLM Haploinsufficiency 
BMP2    
BMP4    
BMPR1A MIM601299  Velkjent predisposisjons gen 
BRCA1 MIM113705  Velkjent predisposisjons gen 
BRCA2 MIM600185  Velkjent predisposisjons gen 
BUB1 (de Voer et al., 
2013)[70] 
  
BUB1B MIM602860   
BUB3 (de Voer et al., 2013)   
CCDC18 (Gylfe et al., 2013) FCC  
CCND1 MIM168461   
CCND2    
CDH1 MIM192090 CRC +HDGC Velkjent predisposisjons gen 
CDKN1A    
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Gene References Association with 
syndrome 
Comment 
CENPE (DeRycke et al.,2013) FCC  
CHEK2 MIM604373   
CTNNB1    
DCC MIM120470   
DCLRE1A    
DSG4    
DUSP10    
DUSP4    
EIF3C    
EIF3H    
ENG MIM131195 JPS  
EPCAM MIM185535   
EPHB2 (Kokko et al., 
2006)[37] 
FCC  
EXO1 MIM606063   
FAM166A    
FANCD2    
FANCM    
FLCN MIM607273 BHDS  
GALNT12 MIM608812 CRC  
GREM1 MIM603054   
HELQ    
KIF23 (DeRycke et al.,2013) FCC  
KIT MIM164920 FGST  
KLLN MIM612105 CS Germline epigenetic regulation 
(methylation) 
LAMA3    
LAMA5    
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Gene References Association with 
syndrome 
Comment 
LAMB4    
LAMC1    
LAMC3    
LIG1    
LUC7L    
MAML3    
MCC MIM159350 Finner ingen bevis DeRyke mener kjent gen 
MLH1 MIM120436 LS Velkjent predisposisjons gen 
MLH3 MIM604395 LS  
MRPL3 (Gylfe et al., 2013) FCC  
MSH2 MIM609309 LS Velkjent predisposisjons gen 
MSH3 (Duraturo et al.,2011) LS Low-risk allele 
MSH6 MIM600678 LS Velkjent predisposisjons gen 
MUTYH MIM604933  Velkjent predisposisjons gen 
MYC    
MYH11 MIM160745 PJS Recessive inheritance 
NABP1    
NOTCH3    
NUDT7 (Gylfe et al., 2013) FCC  
OGG1 (Smith et al., 
2013)(Kim et al., 
2004)[35, 36] 
FCC Low-risk allele 
PCNA    
PICALM    
PIK3CA MIM171834 CS  
PITX1    
PLA2G2A MIM172411   
PMS1 Ingen bevis i OMIM  DeRyke mener kjent gen 
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Gene References Association with 
syndrome 
Comment 
PMS2 MIM600259 LS Velkjent predisposisjons gen 
PMS2CL    
POLD1 (Esteban-Jurado et al., 
2014)(Palles et al., 
2013) 
  
POLD2    
POLD3    
POLD4    
POLE (Esteban-Jurado et al., 
2014)(Palles et al., 
2013)[8, 17] 
  
PPP1CB    
PRADC1 (Gylfe et al., 2013) FCC  
PRSS37 (Gylfe et al., 2013) FCC  
PSPH (Gylfe et al., 2013) FCC  
PTCHD3    
PTEN MIM601728 CS  
PTPRJ MIM600925   
RAI1    
RFC1    
RFC2    
RFC3    
RFC4    
RFC5    
RHPN2    
RPA1    
RPA2    
RPA3    
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Gene References Association with 
syndrome 
Comment 
SFXN4 (Gylfe et al., 2013) FCC  
SHROOM2    
SLC5A9    
SMAD4 MIM600993  Velkjent predisposisjons gen 
SMAD7 MIM602932   
STK11 MIM602216   
TBX3    
TERC    
TERT    
TGFBR2 MIM190182   
TKT    
TLR2 MIM603028   
TLR4 MIM603030   
TP53 MIM191170   
TRA2A    
TREX2    
TWSG1 (Gylfe et al., 2013) FCC  
UACA (Gylfe et al., 2013) FCC  
UBAP2    
USP6NL    
ZFP14    
ZMYM5    
ZNF490 (Gylfe et al., 2013) FCC  
 
 
 
68 
 
6.5 64 variants colour coded according to predictions with Alamut 
A list of variants after filtration with information on each variant from Alamut. 
The variants in red have a mutation that is predicted of all programs to be damaging to the protein, the 
variants colour coded with yellow have a mutation that can be damaging to the protein but the 
prediction programs in Alamut are contradictory and the variants in green have a mutation that is not 
damaging for the protein. The prediction programs in Alamut were not able to collect information 
about the frameshift mutations and that is the reason why N/A (not applicable) is written in these 
fields.  
 
Gene Patients Nomenclature AlignGVGD SIFT MutationTaster Polyphen-2 
FANCD2 30 NM_033084.3
:c.1279G>T:p.
V427F 
Class C0  Deleterious
(score 0.01) 
Disease causing 
(P-value:1) 
Probably 
damaging(Hu
mdiv 1.00 
+humvar pred 
0,997) 
KIF23 71 NM_138555.2 
c.610_618del 
p.Phe204_Lys
206del 
N/A N/A N/A N/A 
KIF23 6 NM_138555.2 
c.622G>C 
p.Glu208Gln 
Class C0  Tolearated 
(score 0.26) 
Disease causing 
(P-value: 1) 
Possibly 
damaging 
(Humdiv 
0.873 + 
humvar 0.588) 
LAMA3 80 NM_198129.1 
c.8693A>G 
Class C45 Deleterious
(score 0) 
Disease causing 
(P-value: 1) 
Probably 
damaging(Hu
mdiv 0.999 
+humvar pred 
0.996) 
RAI1 35,48 NM_030665.3 
c.867_872del 
p.Gln290_Gln
291del 
N/A N/A N/A N/A 
LAMA5 3 NM_005560:c.
9691C>T:p.P3
231S 
Class C0  Tolerated 
(score 0.9) 
Polymorphism (P-
value: 1) 
Benign 
(Humdiv 
0.002 + 
humvar 0.003) 
LAMA5 13 NM_005560:c.
7655C>T:p.T2
552M 
Class C0  Tolerated 
(score 0.23) 
Polymorphism (P-
value: 1) 
Benign 
(Humdiv 
0.029 + 
humvar 0.002) 
69 
 
Gene Patients Nomenclature AlignGVGD SIFT MutationTaster Polyphen-2 
LAMA5 29 NM_005560:c.
8822C>T:p.T2
941M 
Class C0  Tolerated 
(score 0.05) 
Disease causing 
(P-value: 0.997) 
Probably 
damaging 
(Humdiv 
1.000 + 
humvar 0.962) 
LAMA5 38 NM_005560:c.
2918C>T:p.T9
73M 
Class C0  Deleterious 
(score 0.03) 
Disease causing 
(P-value: 0.95) 
Possibly 
damaging(Hu
mdiv 0.830) 
Benign(humva
r 0.177) 
LAMA5 
  
52 NM_005560:c.
3575T>C:p.I1
192T 
Class C0  Tolerated 
(score 0.31)  
Polymorphism (P-
value: 1) 
Benign(Humdi
v 0.023 + 
humvar 0.010) 
LAMA5 80 NM_005560:c.
11015G>A:p.
R3672Q 
Class C0 Tolerated 
(score 0.41) 
Polymorphism (P-
value: 1) 
Benign(Humdi
v 0.004 + 
humvar 0.008) 
LAMC1 14,51,71,79 NM_002293:c.
4579_4580del:
p.Leu1527Gly
fs*7 
N/A N/A N/A N/A 
LAMC1 77 NM_002293:c.
2426A>G:p.D
809G 
Class C65  Deleterious Disease causing 
(P-value: 1) 
Probably 
damaging 
(Humdiv 
1.000 + 
humvar 1.000) 
BUB1B 11,45,50,62 NM_001211:c.
2252_2253ins
AGA:p.Pro751
_Lys752insAs
p 
N/A N/A N/A N/A 
BUB1B 11,45,62 NM_001211:c.
2253_2254ins
CGG:p.Pro751
_Lys752insAr
g 
N/A N/A N/A N/A 
BUB1B 40 NM_001211:c.
800A>C:p.Q2
67P 
Class C0  Tolerated Polymorphism (P-
value: 1) 
Benign 
(Humdiv 
0.000 + 
humvar 0.000) 
MAML3 3,37 NM_018717:c.
1513_1514del:
p.Gln505Alafs
*21 
N/A N/A N/A N/A 
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Gene Patients Nomenclature AlignGVGD SIFT MutationTaster Polyphen-2 
MAML3 3,18,34,41,
52,59,64,77
,90 
NM_018717:c.
1506delG:p.Gl
n502Hisfs*20 
N/A N/A N/A N/A 
MAML3 31 NM_018717:c.
755T>G:p.I25
2S 
Class C0  Deleterious 
(score 0) 
Disease causing 
(P-value: 0.874) 
Benign 
(Humdiv 
0.090 + 
humvar 0.046) 
MAML3 59 NM_018717:c.
1713G>C:p.M
571I 
        
MAML3 92 NM_018717:c.
53T>C:p.I18T 
Class C0  Deleterious 
(Score 0) 
Disease causing 
(P-value: 0.991) 
Possibly 
damaging 
(Humdiv 
0.952 + 
humvar 0.521) 
APC 14,24,46,47
,49,59-
61,72,95 
NM_0011275
11:c.3086_308
7insTCGG:p.L
ys1030Argfs*
2 
N/A N/A N/A N/A 
POLE 5,23,39 NM_006231:c.
229C>T:p.R77
C 
Class C0  Deleterious 
(score 0.02) 
Disease causing 
(P-value: 1) 
Probably 
damaging 
(Humdiv 
0.997) 
Possibly 
damaging 
(humvar0.696) 
POLE 6,29,30 NM_006231:c.
1373A>T:p.Y
458F 
Class C0  Deleterious 
(score 0) 
Disease causing 
(P-value: 1) 
Probably 
damaging 
(Humdiv 
1.000 + 
humvar 1.000) 
POLE 44 NM_006231:c.
824A>T:p.D2
75V 
Class C0  Deleterious 
(score 0) 
Disease causing 
(P-value:1) 
Probably 
damaging 
(Humdiv 
1.000 + 
humvar 1.000) 
POLE 51 NM_006231:c.
2644A>G:p.N
882D 
Class C0  Tolerated 
(score 0.07) 
Disease causing 
(P-value: 0.997) 
Benign 
(Humdiv 
0.001 + 
humvar 0.007) 
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Gene Patients Nomenclature AlignGVGD SIFT MutationTaster Polyphen-2 
POLE 95 NM_006231:c.
4307G>A:p.R
1436Q 
Class C0  Deleterious 
(score 0.03) 
Disease causing 
(P-value: 1) 
Probably 
damaging 
(Humdiv 
0.970) 
Possibly 
damaging 
(humvar 
0.522) 
GREM1 30,31,60 NM_013372:c.
196_197insT:p
.Thr66Ilefs*35 
N/A N/A N/A N/A 
LAMB4 78 NM_007356:c.
5265delA:p.Ly
s1755Asnfs*1
1 
N/A N/A N/A N/A 
UBAP2 41 NM_018449:c.
212G>T:p.C71
F 
Class C0  Deleterious 
(score 0.01) 
Disease causing 
(P-value: 1) 
Probably 
damaging 
(Humdiv 
1.000 + 
humvar 0.995) 
UBAP2 55 NM_0012825
30:c.218G>A:
p.R73Q 
        
UBAP2 65 NM_0012825
29:c.596G>A:
p.R199Q 
        
PTCHD3 44 NM_0010348
42:c.1853A>G
:p.Y618C 
Class C0  Deleterious 
(score 0.02) 
Disease causing 
(P-value: 0.986) 
Probably 
damaging 
(Humdiv 
0.996 + 
humvar 0.997) 
AXIN2 27 NM_004655:c.
769G>T:p.A2
57S 
Class C0 Tolerated 
(score 0.07) 
Disease causing 
(P-value: 0.999) 
Benign 
(Humdiv 
0.212 + 
humvar 0.040) 
FAM166
A 
16,22,52 NM_0010017
10:c.751_752d
el:p.Leu251Va
lfs*2 
N/A N/A N/A N/A 
NOTCH3 34 NM_000435:c.
3733_3734ins
T:p.Thr1245Il
efs*20 
N/A N/A N/A N/A 
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Gene Patients Nomenclature AlignGVGD SIFT MutationTaster Polyphen-2 
NOTCH3 40 NM_000435:c.
6532C>T:p.P2
178S 
Class C0 Tolerated 
(score 0.53) 
Disease causing 
(P-value: 0.64) 
Benign 
(Humdiv 
0.012 + 
humvar 0.006) 
NOTCH3 86 NM_000435:c.
2953C>T:p.R9
85C 
Class C35  Deleterious 
(score 0.01) 
Disease causing 
(P-value: 0.999) 
Probably 
damaging 
(Humdiv 
0.994) 
Possibly 
damaging 
(humvar 
0.726) 
ATM 65 NM_000051:c.
7308A>C:p.R
2436S 
Class C65  Deleterious 
(score 0) 
Disease causing 
(P-value: 1) 
Probably 
damaging 
(Humdiv 
0.998 + 
humvar 0.966) 
DCC 23 NM_005215:c.
1817C>G:p.P6
06R 
Class C0  Deleterious 
(score 0) 
N/A Probably 
damaging 
(Humdiv 
0.999 + 
humvar 0.997) 
DCC 46 NM_005215:c.
1664_1665ins
CGAGAT:p.A
sn555_Gly556
insGluIle 
N/A N/A N/A N/A 
AKT1 32 NM_0010144
31:c.206G>C:
p.R69P 
Class C35  Deleterious 
(score 0.01) 
Disease causing 
(P-value: 0.995) 
Possibly 
damaging 
(Humdiv 
0.792 + 
humvar 0.667) 
AKT1 46 NM_0010144
31:c.520C>T:p
.R174C 
Class C0  Deleterious 
(score 0) 
Disease causing 
(P-Value: 1) 
Possibly 
damaging 
(Humdiv 
0.900 + 
humvar 0.800) 
FANCM 17,28 NM_020937:c.
5607_5608del:
p.Glu1870Asp
fs*4 
N/A N/A N/A N/A 
BUB1 49,65 NM_ 
004336.4: c. 
447_448insTC
T 
N/A N/A N/A N/A 
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p.Glu149_Thr
150insSer 
Gene Patients Nomenclature AlignGVGD SIFT MutationTaster Polyphen-2 
PTEN 35,48 NM_000314:c.
377C>T:p.A12
6V 
Class C0 Tolerated 
(score 0.29) 
Disease causing 
(P-value: 1) 
Probably 
damaging 
(Humdiv 
1.000 + 
humvar 0.998) 
BRCA1 49 NM_ 
007300.3. 
c.889A>G 
p.Met29Val 
Class C0  Deleterious 
(score 0.04) 
Polymorphism (P-
value: 0.946) 
Benign 
(Humdiv 
0.074 + 
humvar 0.041) 
STK11 60 NM_000455:c.
459_460insA
GA:p.Ala153_
His154insArg 
N/A N/A N/A N/A 
ZFP14 14 NM_020917:c.
43T>C:p.F15L 
Class C0  Deleterious 
(score 0) 
Disease causing 
(P-value: 0.75) 
Probably 
damaging 
(Humdiv 
0.999 + 
humvar 0.914) 
SLC5A9 66 NM_0011351
81.1. 
c.1194G>T 
p.Leu398Phe 
Class C15  Deleterious 
(score 0) 
Disease causing 
(P-value: 1) 
Probably 
damaging 
(Humdiv 
1.000 + 
humvar 0.999) 
OGG1 26 NM_016821.2
:c.412A>G:p.I
138V 
Class C0  Tolerated 
(score 1) 
Polymorphism (P-
value: 1) 
Benign 
(Humdiv 
0.000 + 
humvar 0.002) 
PIK3CA 38 NM_006218:c.
107_108insA
GAT:p.Cys36f
s* 
N/A N/A N/A N/A 
TBX3 66 NM_016569.3
. c.1893del 
p.Asn632Thrfs
*257 
N/A N/A N/A N/A 
DUSP10 85 NM_007207:c.
868C>A:p.L29
0I 
Class C0 Tolearated 
(score 0.35) 
Disease causing 
(P-value: 1) 
Possibly 
damaging 
(Humdiv 
0.907) Benign 
(Humvar 
0.346) 
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Gene Patients Nomenclature AlignGVGD SIFT MutationTaster Polyphen-2 
BMPR1A 32 NM_004329:c.
785T>C:p.V26
2A 
Class C0 Tolerated 
(score 0.15) 
Disease causing 
(P-value: 1) 
Possibly 
damaging 
(Humdiv 
0.923 + 
humvar 0.884) 
TGFBR2 10 NM_0010248
47.2. 
c.1292C>T 
p.Pro431Leu 
Class C15  Deleterious 
(score 0.01) 
Disease causing 
(P-value: 1) 
Benign 
(Humdiv 
0.117 + 
humvar 0.123) 
FLCN 74 NM_144997:c.
1508G>C:p.C
503S 
Class C0 Tolerated 
(score 0.39) 
Disease causing 
(P-value: 1) 
Possibly 
damaging 
(Humdiv 
0.907) Benign 
(humvar 
0.201) 
BGLAP  80 NM_199173:c.
217G>A:p.V7
3M 
Class C0 Tolerated 
(score 0.24) 
Polymorphism (P-
value: 0.739) 
Possibly 
damaging 
(Humdiv 
0.779) Benign 
(humvar 
0.304) 
LAMC3 61 NM_006059:c.
1145C>T:p.P3
82L 
Class C0  Tolerated 
(score 0.05) 
Disease causing 
(P-value: 1) 
Probably 
damaging 
(Humdiv 
0.999 + 
humvar 0.980) 
USP6NL 81 NM_0010804
91:c.1562T>C:
p.M521T 
Class C0  Tolerated 
(score 0.14) 
Polymorphism (P-
value: 1) 
Benign 
(Humdiv 
0.000 + 
humvar 0.000) 
PPP1CB 72 NM_002709:c.
469_470insA
GATC:p.Cys1
57* 
N/A N/A N/A N/A 
KLLN 58 NM_0011260
49:c.454C>T:p
.P152S 
Class C65  Deleterious 
(score 0) 
Polymorphism (P-
value: 1) 
Possibly 
Damaging 
(Humdiv 
0.728) Benign 
(humvar 
0.358) 
TLR2 29 NM_003264:c.
728C>A:p.S24
3Y 
Class C0  Tolerated 
(score 0.21) 
Polymorphism (P-
value: 1) 
Benign 
(Humdiv 
0.240 + 
humvar 0.061) 
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Gene Patients Nomenclature AlignGVGD SIFT MutationTaster Polyphen-2 
PTPRJ 67 NM_002843:c.
2017G>T:p.V
673L 
Class C0  Tolerated 
(score 0.76) 
Polymorphism (P-
value: 1) 
Benign 
(Humdiv 
0.000 + 
humvar 0.004) 
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6.6 List of mean coverage for each sample  
An overview of mean coverage for each sample and mean coverage of total samples 
Sample nr. Coverage mean 
1 217,91 
2 155,14 
3 284,05 
4 316,01 
5 225,70 
6 223,10 
7 248,41 
8 239,04 
9 219,28 
10 377,72 
11 262,86 
12 238,36 
13 272,21 
14 302,66 
15 294,23 
16 254,96 
17 213,41 
18 201,69 
19 279,53 
20 281,70 
21 322,03 
22 270,34 
23 245,22 
24 270,31 
77 
 
Sample nr. Coverage mean 
25 203,44 
26 335,31 
27 267,49 
28 244,50 
29 295,02 
30 291,44 
31 226,33 
32 118,72 
33 452,88 
34 248,16 
35 260,02 
36 233,52 
37 229,98 
38 482,46 
39 260,85 
40 301,82 
41 272,62 
42 312,87 
43 168,09 
44 272,11 
45 241,66 
46 259,53 
47 226,98 
48 157,87 
49 225,70 
50 210,06 
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Sample nr. Coverage mean 
51 183,92 
52 240,90 
53 185,95 
54 222,56 
55 238,25 
56 206,00 
57 207,38 
59 278,21 
60 250,28 
61 283,00 
62 332,20 
63 247,79 
64 199,13 
65 194,97 
66 230,95 
67 429,97 
68 238,43 
69 258,52 
70 214,06 
71 242,11 
72 307,74 
73 289,34 
74 280,99 
75 362,32 
76 167,66 
77 211,47 
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Sample nr. Coverage mean 
78 235,08 
79 234,21 
80 191,96 
81 285,06 
82 316,37 
83 237,52 
84 274,00 
85 272,22 
86 257,62 
87 317,13 
88 291,38 
89 217,64 
90 243,84 
91 225,68 
92 243,00 
93 302,79 
94 234,70 
95 298,84 
96 329,03 
Sum: 24527,47 
Mean coverage 258,18 
Standard deviation 57,76 
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6.7 Target regions covered with >20 reads 
Overview of % target regions covered with >20 reads 
Sample #regions #regions_covered>20 Percentage 
1 2493 2137 85,72 
2 2493 2065 82,83 
3 2493 2141 85,88 
4 2493 2168 86,96 
5 2493 2114 84,80 
6 2493 2173 87,16 
7 2493 2140 85,84 
8 2493 2157 86,52 
9 2493 2168 86,96 
10 2493 2209 88,61 
11 2493 2136 85,68 
12 2493 2158 86,56 
13 2493 2161 86,68 
14 2493 2172 87,12 
15 2493 2129 85,40 
16 2493 2170 87,04 
17 2493 2152 86,32 
18 2493 2129 85,40 
19 2493 2179 87,40 
20 2493 2198 88,17 
21 2493 2204 88,41 
22 2493 2212 88,73 
23 2493 2175 87,24 
24 2493 2207 88,53 
25 2493 2094 84,00 
26 2493 2172 87,12 
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Sample #regions #regions_covered>20 Percentage 
27 2493 2106 84,48 
28 2493 2147 86,12 
29 2493 2146 86,08 
30 2493 2162 86,72 
31 2493 2109 84,60 
32 2493 2008 80,55 
33 2493 2232 89,53 
34 2493 2157 86,52 
35 2493 2161 86,68 
36 2493 2138 85,76 
37 2493 2154 86,40 
38 2493 2278 91,38 
39 2493 2188 87,77 
40 2493 2216 88,89 
41 2493 2200 88,25 
42 2493 2239 89,81 
43 2493 2117 84,92 
44 2493 2207 88,53 
45 2493 2146 86,08 
46 2493 2177 87,32 
47 2493 2179 87,40 
48 2493 2084 83,59 
49 2493 2150 86,24 
50 2493 2139 85,80 
51 2493 2075 83,23 
52 2493 2143 85,96 
53 2493 2061 82,67 
54 2493 2124 85,20 
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Sample #regions #regions_covered>20 Percentage 
55 2493 2158 86,56 
56 2493 2139 85,80 
57 2493 2126 85,28 
59 2493 2184 87,61 
60 2493 2140 85,84 
61 2493 2167 86,92 
62 2493 2235 89,65 
63 2493 2183 87,57 
64 2493 2144 86,00 
65 2493 2142 85,92 
66 2493 2178 87,36 
67 2493 2265 90,85 
68 2493 2170 87,04 
69 2493 2210 88,65 
70 2493 2161 86,68 
71 2493 2141 85,88 
72 2493 2198 88,17 
73 2493 2183 87,57 
74 2493 2161 86,68 
75 2493 2204 88,41 
76 2493 2087 83,71 
77 2493 2132 85,52 
78 2493 2150 86,24 
79 2493 2138 85,76 
80 2493 2103 84,36 
81 2493 2174 87,20 
82 2493 2210 88,65 
83 2493 2145 86,04 
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Sample #regions #regions_covered>20 Percentage 
84 2493 2173 87,16 
85 2493 2184 87,61 
86 2493 2178 87,36 
87 2493 2204 88,41 
88 2493 2194 88,01 
89 2493 2171 87,08 
90 2493 2166 86,88 
91 2493 2141 85,88 
92 2493 2159 86,60 
93 2493 2210 88,65 
94 2493 2178 87,36 
95 2493 2227 89,33 
96 2493 2196 88,09 
Sum: 
 
205372 8237,95 
Mean: 
 
2162 86,72 
Standard deviation: 
 
42,92 
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6.8 Number of variants found in each patient before filtration 
 
Patient nr. Number of 
Variants 
In total genes 
1 295 78 
2 345 83 
3 305 85 
4 319 80 
5 297 78 
6 334 83 
7 319 85 
8 314 84 
9 338 83 
10 272 76 
11 321 84 
12 327 74 
13 310 81 
14 316 83 
15 321 80 
16 329 81 
17 319 85 
18 341 81 
19 344 79 
20 332 88 
21 330 84 
22 317 88 
23 312 86 
24 317 83 
25 326 84 
85 
 
Patient nr. Number of 
Variants 
In total genes 
26 318 79 
27 296 74 
28 323 82 
29 306 78 
30 304 85 
31 311 78 
32 351 85 
33 305 80 
34 303 78 
35 315 87 
36 344 81 
37 340 85 
38 285 77 
39 306 79 
40 302 78 
41 301 78 
42 293 79 
43 338 83 
44 329 83 
45 316 83 
46 338 77 
47 325 84 
48 332 81 
49 318 76 
50 324 82 
51 316 78 
52 315 86 
86 
 
Patient nr. Number of 
Variants 
In total genes 
53 304 77 
54 335 78 
55 333 81 
56 328 81 
57 357 85 
59 319 87 
60 326 82 
61 298 80 
62 304 82 
63 320 81 
64 318 82 
65 320 80 
66 318 85 
67 272 75 
68 332 79 
69 319 79 
70 335 80 
71 321 81 
72 301 82 
73 317 86 
74 306 79 
75 309 85 
76 340 83 
77 331 82 
78 348 80 
79 316 81 
80 337 80 
87 
 
Patient nr. Number of 
Variants 
In total genes 
81 324 80 
82 306 75 
83 340 90 
84 324 82 
85 336 78 
86 298 72 
87 297 78 
88 296 78 
89 304 77 
90 300 77 
91 323 81 
92 297 84 
93 305 83 
94 347 86 
95 309 82 
96 284 79 
   
88 
 
6.9 Number of variants found in each patient after filtration 
 
Patient nr. Number of 
variants 
In total genes 
1 17 12 
2 16 13 
3 15 13 
4 14 13 
5 14 12 
6 18 14 
7 16 14 
8 16 13 
9 21 15 
10 13 10 
11 16 12 
12 19 16 
13 15 13 
14 16 13 
15 14 12 
16 18 15 
17 19 15 
18 17 14 
19 21 16 
20 18 15 
21 14 12 
22 21 16 
23 17 14 
24 16 13 
25 19 15 
26 17 14 
27 17 14 
28 20 16 
29 18 15 
30 15 13 
31 19 15 
32 18 14 
33 14 11 
34 15 13 
35 18 15 
36 19 14 
37 18 15 
89 
 
Patient nr. Number of 
variants 
In total genes 
38 14 12 
39 20 16 
40 17 14 
41 15 12 
42 21 17 
43 21 15 
44 21 16 
45 18 15 
46 18 14 
47 24 19 
48 17 12 
49 17 13 
50 24 18 
51 21 17 
52 17 14 
53 14 12 
54 17 14 
55 20 15 
56 22 16 
57 21 16 
59 24 19 
60 17 14 
61 17 13 
62 11 9 
63 17 14 
64 21 16 
65 20 16 
66 21 16 
67 11 9 
68 18 15 
69 16 12 
70 15 12 
71 21 17 
72 12 10 
73 18 14 
74 15 12 
75 13 11 
76 20 15 
77 21 16 
78 18 13 
90 
 
Patient nr. Number of 
variants 
In total genes 
79 21 18 
80 16 13 
81 16 13 
82 16 13 
83 16 13 
84 15 12 
85 17 14 
86 15 12 
87 17 14 
88 16 13 
89 21 16 
90 18 14 
91 17 14 
92 19 15 
93 17 13 
94 23 18 
95 19 14 
96 13 9 
 
 
